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ABSTRACT
Valosin-containing protein (VCP/p97) is an essential AAA+ ATPase that is critical
to numerous important cellular pathways, such as ER-associated degradation. p97
works in concertwith a repertoire of adaptor proteins to extract ubiquitylated proteins
frommembranes or complexes and, often, target them for degradation by the protea-
some. The nature of the p97 system—dependent upon a complex network of acces-
sory proteins and targeted to substrates that are unstable and heterogeneous—makes
the mechanism of substrate processing challenging to study. Here, we developed
in vitro biochemical assays to reconstitute two important steps in the p97 pathway
for mechanistic study: adaptor binding and substrate processing. We showed that
p97-adaptor complexes are highly dynamic, recapitulating observations made in cell
lysate. Using a model p97 substrate, we demonstrated for the first time that p97
processes its substrates through unfolding, a fact long presumed but never explic-
itly proven. Finally, with these model systems in hand, we explored the effects of
p97 mutations that cause the neurodegenerative disease multisystem proteinopathy
(MSP) on p97-adaptor-substrate complexes. MSP mutations cause faster substrate
unfolding, and we hypothesize that this increase is due to a higher affinity for the
requisite adaptors Ufd1-Npl4. Our biochemical data presents evidence for a gain of
function model for MSP pathology and suggests new avenues for treating MSP.
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1C h a p t e r 1
INTRODUCTION TO THE AAA+ ATPASE VCP/P97
1.1 The ubiquitin-proteasome system (UPS)
Cellular processes depend upon the spatiotemporal coordination of proteins;
therefore, maintenance of the proteome is critical for cell survival. Many path-
ways are involved in proteostasis, including protein synthesis and trafficking. The
ubiquitin-proteasome system (UPS) contributes to proteostasis by controlling pro-
tein degradation. In addition to its roles in programmed cellular pathways such as
signal transduction, the cell cycle, and stress response, the UPS is also responsible
for protein quality control (PQC), or the clearance of damaged or misfolded pro-
teins. The roles of the UPS and PQC underscore their importance in human health;
programmed protein degradation is particularly important during development, and
PQC pathways are challenged during aging (1, 2). Modulators of the UPS are being
developed to treat a range of diseases, including viral infections, Alzheimer’s, cystic
fibrosis, type II diabetes, and cancer (1–3).
Figure 1.1 shows a summary scheme of the UPS. The 76-amino acid protein
ubiquitin (Ub)—nicknamed the "molecular kiss of death’—serves as a degradation
signal for proteins targeted to the UPS. Chains of ubiquitin are appended to proteins
through a ubiquitylation cascade involving three types of enzymes (4). First, the
C-terminus of ubiquitin forms a thioester linkage with an active site cysteine in an
E1 ubiquitin-activating enzyme, consuming ATP. Next, the ubiquitin is passed from
the E1 enzyme to a cysteine in an E2 ubiquitin-conjugating enzyme. This charged
E2 works in conjunction with an E3 ubiquitin ligase to catalyze the formation of an
isopeptide bond between the C-terminus of ubiquitin and the side chain of an internal
lysine in the target protein. The E2/E3 cycle is repeated to form chains of ubiquitin
by adding ubiquitin instead to an internal lysine in the ubiquitin already conjugated to
the target protein (5). Ubiquitin contains seven internal lysines and an N-terminus
that can serve as acceptors for ubiquitin modification. Specific ubiquitin chain
linkage types are associated with both degradative and non-degradative functions
such as signaling (6), and chains linked through lysine 48 (K48) are most associated
with degradation (7). Chains of four or more ubiquitins recruit the proteasome (8),
a 2.5 MDa protein assembly that unfolds and, using three proteolytic sites, digests
2target proteins into short peptides (9).
Figure 1.1: The ubiquitin proteasome system. First, the C-terminus of ubiquitin is ligated onto an active site
cysteine of an E1 in an ATP-dependent manner, forming a thioester linkage. The ubiquitin is then transferred
to an active site cysteine in an E2. The E2, along with an E3, transfers the ubiquitin to a lysine in the target
protein, forming an isopeptide bond. The cycle repeats to build up chains of ubiquitin formed between the
C-terminus of ubiquitin and an internal lysine in ubiquitin, often K48-linked. This polyubiquitin chain recruits
the proteasome, which digests the target protein into peptides.
1.2 The p97 system
Sometimes proteins targeted to the UPS are in contexts that make them in-
accessible to the proteasome. For example, these proteins may be embedded in
a membrane or part of a large macromolecular assembly. In these cases, the cell
employs p97 to aid in degradation. p97, also called valosin-containing protein
(VCP) or Cdc48 in yeast, is a highly abundant AAA+ ATPase (ATPase associated
with various cellular activities). p97 acts as an unfoldase and segregase, extracting
and unfolding proteins to facilitate their delivery to the proteasome. Numerous
cellular pathways rely on p97 activity, such as DNA repair and cell cycle control
(Figure 1.2) (10, 11), and the most well-studied of the p97-dependent pathways is
endoplasmic reticulum-associated degradation (ERAD) (12). p97 also functions in
some non-degradative pathways that require the action of an unfoldase or segregase,
such as membrane fusion (10). Due to its role in the UPS, p97 is a target for cancer
therapeutics, and a number of inhibitors have been developed (3, 13–20).
Structurally, p97 is a homohexamer, with its subunits forming a ring around a
central pore. p97 comprises three domains: an N-terminal domain (N), two ATPase
domains (D1 and D2) stacked head-to-tail, and an unstructured C-terminal tail (Fig-
ure 1.3) (22–26). Hydrolysis of ATP by p97 generates its mechanical force from
chemical energy. Each ATPase domain includes two key sequences: the Walker
A motif (GX4GK(T/S), where X is any amino acid), which is responsible for nu-
cleotide binding, and the Walker B motif ((R/K)X3GX3(L/V)h3(D/E), where h is
3Figure 1.2: p97/VCP function. Adapted from (21)
any hydrophobic amino acid), which is responsible for nucleotide hydrolysis (27).
Both D1 and D2 are competent to hydrolyze ATP, but the relative contributions
of the two domains to processing substrates is controversial (28). D1 has a higher
affinity for nucleotide while D2 has a higher hydrolysis rate, leading many to suggest
that D1 plays a structural role while D2 is the main generator of force (28–35). Nu-
merous structural (22–26, 31, 36–43) and biochemical (28, 33, 44–47) studies have
demonstrated the extensive communication among domains during the p97 ATPase
cycle. Our best understanding comes from a set of high resolution cryoelectron
microscopy (cryo-EM) structures of p97 in various nucleotide states (22) (Figure
1.3B). When both domains are in the ADP state, the N-domain is oriented in a
position planar to the D1 ring. Upon binding of ATPγS to D1, the N-domains flip
upward into a position coaxial with respect to the D1-D2 barrel. D2 shows rotation
with respect to the D1 upon binding of ATPγS to D2, which is in agreement with
biochemical studies that suggest a flexible di-glycine linker between D1 and D2 is
critical for domain communication (45, 46).
p97 does not function alone but instead relies upon its interactions with adap-
tor proteins to provide substrate and pathway specificity (Figure 1.3A) (48). Many
adaptors bind ubiquitin or polyubiquitin chains through ubiquitin-associated (UBA)
4Figure 1.3: p97 structure and binding partners. (A) Cartoon representation of a p97 homohexamer showing
three folded domains (N, D1, D2) as well as an unstructured C-terminal tail. Adaptor proteins (orange), many
of which recruit ubiquitin, bind to the N-domains and C-terminal tails. (B) Cryo-EM structures of p97 in two
nucleotide states. Upon exchange of ADP for ATPγS in both D1 and D2, the N-domains move from a coplanar
to a coaxial position with respect to the D1-D2 barrel, and D2 rotates downward. PDB #5FTK and #5FTN (22)
domains (49–51) or other specialized domains (33, 52), which recruit UPS sub-
strates to p97. Other adaptors serve to process substrates through post-translational
modifications (PTMs), such as addition of ubiquitin through E3 ligases, removal
of ubiquitin by deubiquitinating enzymes (DUBs), or removal of oligosaccharides
(53–57). Previous research has implicated some adaptors in specific p97 pathways
(58–62); for example, p47 is critical for Golgi reassembly after mitosis (63, 64).
However, the functions of many adaptors are still unclear (49, 51). Further compli-
cating our understanding of the p97-adaptor network is the fact that some adaptors
are able to co-bind p97 while other adaptors are mutually-exclusive binders (49, 65,
66).
Most adaptors bind to the N-domains or C-terminal tails of the p97 hexamer
with various stoichiometries (27, 51, 66, 67) (Figure 1.3A). Two p97 adaptors are
notable exceptions and bind in unqiue ways. First, ubiquitin regulatory X domain-
containing protein 9 (UBXD9) disassembles p97 hexamers to bind p97 monomers
instead (68, 69). Second, ubiquitin regulatory X domain-containing protein 1
(UBXD1) binds both to the N-domain and the D1-D2 barrel of p97 hexamers (70,
71). A few common p97 binding motifs are employed by adaptors that bind to the
N-domains. The ubiquitin regulatory X (UBX) domain, found in thirteen adaptors,
interacts with the hydrophobic groove of an N-domain through an R...FPR motif
(49–51, 72, 73). The VCP-interacting motif (VIM) binds to a similar surface on N-
5domains using the consensus sequences RX5A2X2R and A2X2R (71, 74), while the
SHPmotif binds to a separate site on theN-domains using the sequence FXGXGX2H
(43, 75).
Binding of adaptors alters the struture and activity of p97 hexamers. Low-
resolution cryo-EM structures of p97 in complex with various adaptors suggest that
the N-domains must be in an axial position with respect to D1-D2 for adaptors to
bind to the N-domains, biasing the conformations that p97 samples (36, 66, 67,
76–78). Adaptor binding to N-domains also propagates conformational changes to
D2 (36, 76). Some adaptors, such as p47, modulate ATPase activity while others,
such as UN, do not (47, 79, 80).
1.3 p97 and neurodegenerative disease
Mutations in p97 have been linked to neurodegenerative diseases such as
amyotrophic lateral sclerosis (ALS) and multisystem proteinopathy (MSP), also
called inclusion body myopathy with Paget’s disease of the bone and frontotempo-
ral dementia (IBMPFD) (81–83). MSP is a fatal disease of the muscle, bone and
brain that develops in middle age (reviewed in (84)). Myopathic symptoms include
atrophy and weakness of the skeletal, cardiac, and respiratory muscles due to intra-
cellular inclusions containing ubiquitin and other proteins such as Tar DNA binding
protein-43 (TDP-43). Paget’s disease of the bone (PDB) causes bone fragility and
deformities due to increased osteoclast activity. Neuronal loss in the frontal and
temporal lobes of the brain due to inclusions containing ubiquitin, TDP-43, and tau
cause loss of reasoning, judgement, and social awareness in frontotemporal demen-
tia (FTD). Not all MSP patients display the same symptoms. Approximately 90%
of patients develop myopathy, approximately 40% of patients develop PDB, and
approximately 30% of patients develop FTD; only around 10% of patients develop
all three disorders (85). While over 50 unique missense mutations in p97 have been
discovered to cause MSP (86), there are no strong correlations between genotype
and phenotype due to the background genetic variability among individuals (85).
1.4 Remaining questions and research aims
While biochemical and structural studies have shed light on some of p97’s
general functions, many fundamental questions about p97 mechanism remain.
6p97-adaptor dynamics
It remains unclear how the vast p97 network is regulated. Little is known about
the dynamics of p97-adaptor association andwhether other factors, such as substrates
or PTMs, affect these processes (48). Previous work in the Deshaies lab began to
answer these questions by examining p97 complexes from cells through a variety of
mass spectrometry (MS) experiments (Figure 1.4)(87). First, the stabilities of p97-
adaptor complexes were probed by immunoprecipitation (IP)-MS. Cells expressing
p97 tagged at the genomic locus with the FLAG epitope were grown in isotopically
“light” media while cells with untagged p97 were grown in “heavy” media. Cell
lysates were incubated with anti-FLAG antibodies, and the captured proteins were
assessed by MS. If the complexes are stable, only light adaptors would be captured
by FLAG-p97, representing endogenous complexes. However, if the complexes are
dynamic, the bound adaptors would be a 1:1 mixture of heavy and light due to
exchange. As seen in Figure 1.4A, most adaptors display rapid exchange, with the
notable exception of UBXD9.
To further validate these dynamics, a competition IP-MS experiment was
performed. Cell lyates were spiked with increasing amounts of a truncated p97
(N-D1-L) which is competent to bind adaptors but is not recognized by the antibody
used for IP. If complexes are stable, the pull-down efficiency of adaptors should be
impervious to added p97-ND1L, but if complexes are unstable, the adaptors should
be chased by added p97-ND1L. With the exception of UBXD9 and UBXD4, all
adaptors were readily depleted in the IP by the addition of exogenous p97-ND1L,
further underscoring the dynamic nature of p97-adaptor interactions (Figure 1.4B).
Additionally, size exclusion chromatography (SEC)-MS was used to assess p97-
adaptor complexes in cell lysate. In agreement with the other MS experiments,
only UBXD4 and UBXD9 were observed to co-elute with p97, suggesting no other
adaptors form stable complexes with p97 (Figure 1.4C).
A multitude of factors could influence the rapid dynamics of the p97-adaptor
network in the cell (48). The proteins themselves could have intrinsically dynamic
interactions, and these interactions could be further modulated by PTMs, oligomeric
states, and conformational changes. Outside factors such as competition for binding
sites or additional binding partners could also affect the network. In the previous
experiments in cell lysate, it is impossible to tease apart the effects of these different
influences; therefore, the first goal of this work is to probe the dynamics of the
p97-adaptor network using an in vitro reconstituted system.
7Figure 1.4: p97-adaptor network is dynamic in cell lysate. (A) Exchange rate of p97 adaptors during IP-MS.
Cells expressing FLAG-p97 and WT p97 were grown in light and heavy media, respectively. Lysates were
incubated with anti-FLAG antibodies for various amounts of time, and the ratio of heavy to light adaptors
recovered was determined by MS. All adaptors show rapid equilibration (as evidenced by a light:heavy ratio
close to 1), except UBXD9. (B) A p97 fragment, ND1L, which can bind adaptors but not the antibody used for
IP, was added in increasing amounts to an IP of cell lysates, and the recovery of adaptor proteins was plotted.
While the p97-UBXD9 complex is insensitive to added p97-ND1L, all other adaptors have reduced recovery
as rapid exchange allows p97-ND1L to compete with full length p97 for adaptor binding. (C) Fractionation
profiles in a SEC-MS experiment for a variety of p97 adaptors. Only UBXD9 and UBXD4 co-elute with p97
after fractionation on a Superose 6 sizing column. All panels are modified from data previously published (87).
Substrate processing by p97
Due to its functions in cellular pathways and its homology to other AAA
machines such as ClpA (88), the proteasome 19S regulatory particle (89, 90),
the VCP-like ATPase from Thermoplasma acidophilum (VAT) (91, 92), and N-
ethylmaleimide-sensitive factor (NSF) (93), most have assumed that p97 remodels
its protein substrates through unfolding. However, this function has never been
explicitly demonstrated. Many AAA ATPases unfold their substrates by feeding
the polypeptide through their central pores (e.g. (94)). However, p97 does not
contain the requisite hydrophobic pore residues in its D1 domain for this threading
mechanism, though other pore residues in D1 have been implicated in substrate
processing (34, 95). Additionally, structural studies of p97 have revealed a narrow
central pore that may not be able to accommodate a threaded polypeptide (22,
25). Many other mechanisms for unfolding have been proposed, such as unfolding
exclusively in the D2 pore through an arginine "denaturation collar" or exclusively
through the N-domain movements without direct participation of the pore, similar
to that of NSF (93, 95).
The special difficulties of studying p97 pathways in vitro have long stymied
8research into these questions. Native p97 substrates are complex, unstable, hetero-
geneous, and highlymodified by ubiquitin, making their purification for biochemical
studies challenging. Therefore, the presumed function of p97—protein unfolding—
has never been directly tested, and previous studies on p97 function have instead
relied on indirect assays, such as measurements of basal ATP hydrolysis rates and
reconstitutions with cellular components (e.g.(95)).
In addition to whether or not p97 is a bona fide unfoldase, many other fun-
damental questions about p97 mechanism remain unanswered. First, the minimal
components necessary to reconstitute substrate processing remains obscure. It is
assumed that p97 requires adaptors to recruit substrates (48), but p97’s multitude of
adaptors complicates our understanding. Though it is unclear what role each adap-
tor may play in substrate unfolding, a good candidate for p97’s general unfolding
partner is the heterodimer Ufd1/UFD1L and Npl4/NPLOC4 (UN), as this adaptor
has been implicated in numerous proteasome-dependent degradative pathways such
as ERAD (10, 65, 96, 97). In particular, UN is a critical component of, and the only
substrate adaptor linked to, the ubiquitin fusion degradation (UFD) pathway, a p97-
dependent degradation process (34, 98). ATP is also likely required for substrate
processing, as ATPase activities in D1 and D2 are critical for substrate processing
in cells (34).
Second, it is unclear what the requirements are for the substrate itself in
order for it to be processed by p97. Unlike the proteasome, p97 does not require
a disordered region on the substrate to initiate processing (34, 99). Due to p97’s
role in PQC, p97-dependent processes have been connected to numerous ubiquitin
linkage types, including K6, K11, K29 and K48 (98, 100–102). In particular, Ufd1
binds K48-linked chains specifically, while Npl4 associates with poly-ubiquitin
chains in a linkage type-independent manner (33, 52, 77). Therefore, it is likely
substrates require ubiquitylation, but the linkage types and chain topologies that
support proessing by p97 are undefined.
In order to address these critical gaps in our understanding of the basic
biochemical activity that underlies p97’s cellular functions, the second aim of this
work is to develop an in vitro reconstitution of p97 substrate processing using
purified components.
9Perturbations caused by p97 disease mutations
The mechanism by which mutations in p97 cause neurodegenerative dis-
eases remains highly controversial. Defects in numerous cellular pathways, such
as autophagy, endosomal trafficking, lysosomal function, mitochondrial homeosta-
sis, ERAD, mTOR regulation, energy balance, aggregate clearance, and NF-κB
signaling (58, 84, 103–114), have all been reported in MSP mutants, yet the under-
lying cellular perturbations that cause disease pathology remains a mystery. On a
more basic level, it even remains unclear whether the the molecular-level defect in
these dominantly-inherited MSP mutations causes a gain or loss of p97 function.
This question is particularly relevant for treatment, as many p97 inhibitors, such as
NMS-873 and CB-5083, have already been developed for cancer treatment (14, 15,
115).
The majority of MSP mutations lie on the interface between the N and D1
domains (83), and in vitro studies have provided some clues as to the effects of these
mutations on p97 structure and enzymology. Under basal conditions, MSP mutants
show an increase in ATPase activity in D2 (28, 47, 116–119). The functional
significance of this activity is hotly debated. Some have speculated that this higher
activity is not a productive gain of function but instead represents an uncoupling
of ATP hydrolysis from mechanochemical transduction in the ring due to severed
communication between the regulatory N domain and the D1 ATPase domain (83,
120). A dominant-negative mechanism in which non-functional mutant protomers
poison the activity of WT-MSP mixed hexamers could then explain the inheritance
pattern of MSP.
Structurally, mutants show an abnormal N-D1 conformation, with the N do-
mains occupying a more axial, ATP-like conformation with respect to D1 regardless
of nucleotide state due to a destabilization of ADP binding (118, 119, 121–124). IPs
from cells suggest altered associations with adaptors in MSP mutants, with some
adaptors being more abundant and others less (116, 125). In particular, the loss
of UBXD1 binding, which is linked to endosomal sorting, has been proposed as a
major cause of disease (58, 126).
With no biochemical assay available to directly test the effects of these muta-
tions on p97’s basic function—protein unfolding—it has been impossible to discern
whether MSP mutants represent a true gain or loss of function. Therefore, the third
aim of this work is to use the tools described above to explore how MSP mutations
perturb adaptor binding and substrate unfolding by p97.
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C h a p t e r 2
PROBING P97-ADAPTOR INTERACTIONS BY FRET
The p97-p47 results and p97-p47 methods were previously published in: Xue, L.,
Blythe, E.E., Freiberger, E.C., Mamrosh, J.L., Hebert, A.S., Reitsma, J.M., Hess,
S., Coon, J.J., and Deshaies, R.J. (2016) Valosin-containing protein (VCP)-adaptor
interactions are exceptionally dynamic and subject to different modulation by a
VCP inhibitor. Mol Cell Proteomics 15, 2970-2986. © the American Society for
Biochemistry and Molecular Biology.
2.1 Introduction
The first goal of this work was to investigate the properties of p97-adaptor
interactions in order to gain mechanistic insight into the how the incredibly dynamic
p97-adaptor network is regulated. We chose two p97-adaptor pairs on which to
focus. First, we developed a fluorescence resonance energy transfer (FRET) assay to
quantify the interaction between p97 and p47. p47, also called NSFL1C, is involved
in Golgi reassmebly after mitosis by binding to syntaxin 5 (63, 64, 127). p47 is
a homotrimer comprising three domains: a UBA domain that preferentially binds
mono-ubiquitin, a SEP domain that mediates trimerization, and a UXB domain (65,
76, 128) (Figure 2.1A). One p47 trimer binds one p97 hexamer through interactions
between both its UBX domain and a SHP motif located in SEP-UBX linker on
separate sites on the p97 N domain (63, 72, 76, 129). p47 was an appealing target
not only because its role in membrane dynamics was well established but also
because a crystal structure of its UBX domain bound to p97-ND1 was published,
facilitating the design of FRET probes (72).
Second, we focused on developing a FRET binding assay for p97-UN. Due
to its participation in a wide array of p97 processes as discussed in Chaper 1, UN
was an important target for this assay. Npl4 comprises a ubiquitin-like domain
(UBD), which binds to the p97 N domain, and a zinc finger (ZF) domain that binds
poly-ubiquitin (65, 130). Ufd1 comprises a UT3 domain which binds ubiquitin, a
SHP motif that binds to the p97 N domain, and an Npl4 binding motif (NDM) (33,
75, 129, 131) (Figure 2.4A). One heterodimer of UN binds one p97 hexamer (65,
80, 129, 130). Similar to p47, a structure of the Npl4 UBD domain bound to the
p97 N domain was published, aiding in FRET assay design (130).
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Using these designed FRET assays of p97-p47 and p97-UN, we demonstrate
that the rapid dynamics of p97-adaptor complexes observed in our previous cell-
basedMS experiments are due to the intrinsic properties of these proteins, suggesting
there is not a requirement for an exogenous factor to facilitate p97-adaptor complex
assembly or disassembly. However, these rapid dynamics suggest that some stabi-
lizing factors may exist to promote the formation of p97-adaptor complexes during
cellular processes. In agreement with structural work, the affinities of these in-
teractions are highly dependent on the nucleotide state of p97, underscoring the
importance of N-domain movement for adaptor binding. Additionally, we observed
enhanced binding of both p47 and UN in MSP mutants, suggesting adaptor balance
defects in mutant cells may underlie some MSP pathology.
2.2 Results
p97-p47
Using the crystal structure of p47 bound to the N-domain of p97 as a guide
(72) (Figure 2.1B), we first mutagenized the C-terminal amino acid (Thr370) of
p47 to cysteine, and then reacted the purified recombinant protein with maleimide-
TAMRA to generate p47TAMRA. For p97, we used the ybbR tagging method (132)
to attach a Cy5 tag at its N terminus (Cy5p97). Upon mixing p47TAMRA and Cy5p97
and exciting with 540 nm light, we observed a significant reduction in TAMRA
fluorescence coupled to an increase in Cy5 emission (Figure 2.2). This FRET
signal was because of specific interaction of p47TAMRA and Cy5p97, because it was
competed by addition of excess unlabeled p97 (Figure 2.2).
By titrating Cy5p97, we estimated a KD of 65 nM for interaction of the two
proteins in the absence of nucleotide (Figure 2.3A and Table 2.1). This affinity
is 10-fold tighter than what was reported from isothermal titration calorimetry
(ITC) studies (50, 76), but is close to the affinity measured in a pair of surface
plasmon resonance (SPR) studies (20–31 nM) (133, 134). However, there are
significant problems with measuring p47-p97 interactions by SPR because of the
oligomeric nature of both proteins. In addition, none of the studies cited above
addressed the crucial issue of the dynamics of p47-p97 interaction. To investigate
binding dynamics, we measured the kon for complex formation and koff for complex
dissociation in the absence of nucleotide (“apo”) or in the presence of ADP or
ATPγS with and without VCP inhibitors. Examples of koff and kon measurements
in the absence of nucleotide are shown in Figures 2.3B and 2.3C, respectively, and
a plot of kobs versus [Cy5p97] that was used to estimate kon is shown in Figure
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Figure 2.1: p97-p47 FRET construct design. (A) Cartoon diagram of p97 (blue) and p47 (orange) showing
domain architecture. (B) Crystal structure of p47 UBX domain bound to p97-ND1, with the positions of FRET
dyes labeled. A mutant p47 (T370C) was labeled with TAMRA donor dye via maleimide chemistry. p97 was
labeled with an N-terminal ybbR tag to which a Cy5 acceptor dye was enzymatically conjugated. PDB#1S3S
2.3D. As shown in Table 2.1, kon values were essentially invariant, ranging from
8–11x107 M-1sec-1 regardless of nucleotide state. Meanwhile, koff showed slightly
more variation, ranging from 2.5 s-1 in the presence of ATP and NMS-873 to 9.5
s-1 in the presence of ADP. Consistent with the lack of an effect of NMS-873 on
co-IP of p47 with p97 from lysates (87), addition of NMS-873 in the presence of
ATP had less than a twofold effect on koff (Table 2.1). These results confirm that
purified p47TAMRA exhibited extremely dynamic association with purified Cy5p97
in accordance with the behavior of these proteins in HEK293 cell extracts, and that
their association was relatively insensitive to modulation by NMS-873.
Figure 2.2: p47TAMRA and Cy5p97 show
FRET. Fluorescence emission spectra of 16.7
nM p47TAMRA trimer, 83.3 nM Cy5p97 hex-
amer, and a mixture excited at 540 nm shows
a 20% loss of TAMRA donor fluorescence in
the presence of Cy5p97. Loss of fluorescence
is prevented by preincubation of p47TAMRA
with 833 nM unlabeled p97 hexamer.
p97-UN
In order to further investigate the dynamics of p97-adaptor complexes, we
developed a FRET assay to probe the p97-UN complex. As shown in Figure 2.4,
the N-termini of p97 and Npl4 are nearby one another. A FRET construct labeling
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Figure 2.3: Example p97-p47 FRET data. (A) Equilibrium titration of 50 nM p47TAMRA trimer with Cy5p97
hexamer in the absence of nucleotide. Fit to a quadratic binding equation yields a KD of 65 ± 7 nM. Error bars
represent S.D., with n=3. (B) Change in donor fluorescence of 50 nM p47TAMRA trimer preincubated with
300 nM Cy5p97 hexamer upon addition of 3 µM unlabeled p97 hexamer in the absence of nucleotide. Curve
was fit to a single exponential to give koff of 4.04 s-1. (C) Change in donor fluorescence of 50 nM p47TAMRA
trimer upon addition of Cy5p97 hexamer at various concentrations in the absence of nucleotide. Curves were fit
to a single exponential. (D) Exponential fits measured in panel (C) plotted against the concentration of Cy5p97
hexamer. Linear slope gives kon of 8.68x107 ± 0.09x107 M-1s-1. Error bars represent S.D., with n=5.
p97 p97-R155H
Buffer
KD
(nM)
(eq)
kon (x107
M-1s-1) koff (s
-1) KD (nM)(koff/kon)
KD
(nM)
(eq)
kon (x107
M-1s-1) koff (s
-1) KD (nM)(koff/kon)
Apo 65 ± 7 8.68 ±0.09
4.04 ±
0.09 47 49 ± 6 9.2 ± 0.1
2.496 ±
0.005 27
ATPγS n.d. 10.5 ±0.1
3.30 ±
0.02 31 n.d.
3.89 ±
0.08
2.04 ±
0.03 52
ADP n.d. 8.30 ±0.07
9.50 ±
0.08 114 n.d. 7.9 ± 0.1
3.44 ±
0.06 44
Apo +
CB-5083 n.d. 8.0 ± 0.1
4.80 ±
0.03 60 n.d.
4.07 ±
0.06
2.06 ±
0.04 51
ATP +
NMS-873 n.d.
11.01 ±
0.01
2.50 ±
0.03 23 n.d.
7.03 ±
0.05
1.98 ±
0.01 28
Table 2.1: Kinetic and equilibrium binding constants for p47TAMRA-Cy5p97.
the N-terminus of Npl4 with a donor TRITC fluorophore via sortase (135) was
designed to complement the Cy5p97 used in the previously described p47-p97 FRET
assay. Incubation of UTRITCNwith Cy5p97 lead to a decrease in TRITC fluorescence,
indicative of FRET (Figure 2.5). Importantly, the loss of fluorescence can be rescued
by the addition of unlabeled UN, providing evidence that this FRET assay is specific
(Figure 2.5).
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Figure 2.4: p97-UN FRET construct design. (A) Cartoon diagram of p97 (blue) and the UN heterodimer
(orange and yellow, respectively) showing domain architecture. Adapted from (75). (B) Structure of Npl4 UBD
domain bound to p97 N domain, with the positions of FRET dyes labeled. The N-terminus of Npl4 was labeled
with a TRITC dye via sortase labeling, while the N-terminus of p97 was labeled with Cy5 via a ybbR tag as
described above for p97-p47 FRET. Composite of PDB #2PJH and #5FTN
With this assay in hand, we were able to measure the equilibrium and kinetic
constants for p97-UN in various nucleotide states (Figure 2.6, Table 2.2). The
equilibrium dissociation constant is 2-fold less in ATP versus ADP and has a further
reduction in ATPγS. These KD measurements are close to that measured by SPR
(100-400 µM) (133) but 2-10-fold tighter than that measured by ITC in the absence
of nucleotide (1.7 µM) (50). SPR studies also observed an increase in UN affinity
when p97 was in an ATP state (133). Due to the low affinity in ADP, we were
able to measure on- and off-rates for the ATP and ATPγS states only (Table 2.2).
The two conditions have similar rates, with ATPγS showing a slightly faster on-rate
and slightly slower off-rate. Compared to p47, UN has a nearly 80-fold slower
on-rate and 10-fold slower off-rate, suggesting that while p97-adaptor dynamics are
generally rapid, variation among adaptors is present.
Figure 2.5: UTRITCN and Cy5p97 show
FRET. Fluorescence emission spectra of 50
nM UTRITCN heterodimer shows a 20% loss
of fluorescence in the presence of 250 nM
Cy5p97 hexamer. Loss of fluorescence is pre-
vented by addition of 2.5 µM unlabeled UN
heterodimer.
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Figure 2.6: Example p97-UN FRET data. (A) Equilibrium KD titration of 50 nM UTRITCN with Cy5p97
hexamer in the presence of ATPγS. Data were fit to a quadratic binding equation. Error bars represent S.D.,
with n=3. (B) Change in donor fluorescence of 50 nM UTRITCN preincubated with 250 nM Cy5p97 upon
addition of 2.5 µM unlabeled UN in the in the presence of ATPγS. Curve was fit to a single exponential to
give koff. (C) Change in donor fluorescence of 50 nM UTRITCN upon addition of 50 nM Cy5p97-A232E in the
presence of ATPγS. Curve was fit to a single exponential to give kobs. (D) Exponential fit like those measured
in panel (C) plotted against the concentration of Cy5p97-A232E. Linear slope gives kon. Error bars represent
S.D., with n=5.
KD (nM) kon (x106 M-1s-1) koff (s-1)
p97 ATP ADP ATPγS ATP ADP ATPγS ATP ADP ATPγS
WT 302 ±51
636 ±
96
177 ±
32
1.3 ±
0.3* n.d.
1.9 ±
0.3*
0.48 ±
0.01 n.d.
0.33 ±
0.01
R155H 6.3 ±0.1* n.d. n.d. 53 ± 1 n.d. n.d.
0.332 ±
0.001 n.d. n.d.
A232E 4.6 ±0.2* 50 ± 11
4.6 ±
0.2* 54 ± 1
3.3 ±
0.7* 61 ± 1
0.25 ±
0.01
0.165 ±
0.003
0.28 ±
0.01
T262A 3.5 ±0.1* n.d. n.d. 60 ± 1 n.d. n.d.
0.210 ±
0.001 n.d. n.d.
Table 2.2: Kinetic and equilibrium binding constants for UTRITCN-Cy5p97. Error represents S.D., with n ≥ 3.
*Calculated from other values.
Effects of disease mutants on adaptor binding
Because pull-downs from cells showed differential adaptor binding in MSP
mutants (125), we were interested in investigating how binding of p47 and UN
changes in MSP mutants. For p47, we measured binding constants for the MSP
mutant R155H in the presence of various nucleotides and inhibitors (Table 2.1). The
largest difference we observed among all parameters was the off-rate in ADP. While
WT p97 has a nearly 3-fold faster off-rate in ADP versus ATPγS, R155H retains a
similar off-rate regardless of nucleotide state. This observation is in agreement with
published SPR data (136). For UN, we measured binding constants for R155H as
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well as two other mutants, A232E and T262A (Table 2.2). We characterized UN
binding of A232E most fully and, as with WT p97, we observed a slower on-rate
and therefore a decrease in affinity in the ADP state compared to ATP or ATPγS.
Strikingly, A232E has a 10-60-fold higher UN affinity compared to WT regardless
of nucleotide state, and this increase is the result of a significantly faster on-rate.
R155H and T262A have very similar affinities to A232E in the presence of ATP,
suggesting that this phenomenon is a common feature of MSP mutations.
Patients with MSP have one mutated allele and one WT allele, so in cells we
expect mixed WT-MSP hexamers to exist. In order to probe the adaptor affinity in
mixed hexamers, we devised a purification scheme to prepare mixed hexamers from
E. coli. WT and His-tagged A232E were co-expressed, and hexamers with different
WT:A232E ratios were broadly pooled into three fractions using a stepwise elution
from a nickel affinity column (Ni-NTA) (Figure 2.7A). The UN affinity of ’Mixed
2’ was indirectly measured by a FRET competition assay (Figure 2.7B). Briefly,
UTRITCN and Cy5A232E were incubated with unlabeled p97 hexamers, and the
inhibition of FRET was measured. The UN binding affinity Ki was then calculated
from a curve fit of IC50 using the known concentrations and KD for A232E-UN. As
seen in Figure 2.7B, the UN affinities for pure WT and A232E hexamers agree fairly
well with thosemeasured directly (Table 2.2), and the affinity for themixed hexamers
falls in between that of the pure hexamers. No protomer exchange occurred during
the time scale of the competition FRET experiment (Figure 2.7C). Therefore, the
UN affinity of p97 titrates with the number of mutant subunits.
2.3 Discussion
The p97-p47 and p97-UN complexes are sensitive to the nucleotide state of
p97, and that these adaptors have high affinity for p97 in an ATP-bound state is in
agreement with published structural information. The N-domains of p97 adopt an
“up” conformation with respect to the ATPase rings in ATP whereas they adopt
a more “down” conformation in ADP (22). Cryo-EM structures of p97-p47 and
p97-UN show the adaptors perched on top of p97, suggesting that the N-domains
need to be in an “up” or ATP-bound conformation to bind adaptor (67, 76, 78).
Both complexes have altered affinities in MSP mutants, which have altered
N-domain conformations. p47 binding becomes insensitive to nucleotide state
with mutant p97, and the same phenomenon has been reported for two other p97
adaptors, valosin-containg protein-interactingmembrane protein (VIMP) and ataxin
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Figure 2.7: WT-A232E mixed hexamer purification and FRET (A) Mixed hexamer purification scheme. WT
and A232E-His were co-expressed in E. coli, and three fractions of mixed hexamers with increasing amounts
of A232E protomers were crudely purified by stepwise elution from a Ni-NTA column. (B) Competition FRET
assay of 25 nM UTRITCN-Cy5A232E by unlabeled p97 in the presence of ATP. Ki was calculated from a curve
fit of IC50 using the known KD for A232E. Error bars represent S.D., with n=3. (C) Protomer exchange is
slow. Cy5p97-His was incubated with anti-FLAG resin in the presence or absence of p97-FLAG for ten minutes.
Coomassie stain and fluorescence scan of an SDS-PAGE gel show no evidence of Cy5p97-His binding to the
resin despite robust binding of p97-FLAG.
(124, 137). UN behaves differently, showing increased affinity for mutant p97 under
all nucleotide conditions. Structural studies have consistently shown than MSP
mutants favor N-domains in an up conformation even in ADP (118, 121, 123, 138),
which would explain why adaptors are able to maintain high affinity interactions
in ADP with mutant p97. Nuclear magnetic resonance (NMR) studies measuring
the dynamics of N domain movements suggest that WT and mutant p97 have
similar up/down equilibrium in ATPγS (121). We still observe a large difference
in UN affinity under those conditions, which would suggest instead that differences
in up/down dynamics remain regardless of nucleotide state. Alternatively, MSP
mutations could be altering p97 structure beyond its normal up/downmovement that
further promotes UN binding. NMR studies with mixed WT and mutant hexamers
demonstrated cooperativity in N domain orientation among adjacent protomers,
which implies that adaptor affinity in mixed hexamers is not linearly related to
the number of mutant protomers (123). Our biochemical data is consistent with
differential adaptor binding to WT versus mutant p97 in IPs from cell lysate, though
the rapid exchange of these factors suggest these interactions were formed in lysate
rather than originating in the cell (116, 125). The significance of these findings
to MSP pathology remains unclear; while some adaptors bind more tightly, other
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adaptors such as UBXD1 conversely lose binding to mutant p97, preferring instead
to bind to the ADP-like down conformation (58, 121, 123). This question will be
addressed more by functional assays in Chapter 4.
The rapid binding kinetics we observe with the p97-p47 and p97-UN com-
plexes are in agreement with the rapid adaptor exchange we observed in cell lystate
by MS, suggesting that some network regulation may come from rapid p97 sam-
pling of adaptors. However, the fast off-rates of adaptors raises the question of how
p97-adaptor complexes can properly function in the cell. The ATPase rate of p97 is
between 0.75-5.2 ATP per second per hexamer (28, 32, 95, 118), yet the off-rates of
adaptors we measured ranged from 0.2-2 per second. In the slowest case, p97-UN
would hydrolyze 3 to 25 ATP per hexamer during the lifetime of the complex, and
in the extreme case of p47, at most 1 to 2 ATP would be hydrolyzed since p47
also retards p97 ATPase activity (47, 79). Given these rates, it is unclear how p97
can engage substrate and sustain unfoldase activity without other mechanisms that
modulate the lifetimes of these complexes. p97 and its adaptors are decorated with
PTMs (48, 139); for example, methylation of p97 at K315 has been proposed to
affect its ATPase activity (140). Covalent modifications or interactions with other
proteins, such as substrates, may serve to stabilize p97-adaptor complexes. Con-
sistent with this hypothesis is the observation that p47 forms an extremely stable
complex with p97 when purified from rat liver yet did not coelute with p97 in our
SEC-MS experiments (63).
2.4 Methods
p97-p47 FRET reagents
Full-length p97 was amplified by PCR from human p97 pET15T (28) and
ligated into pET24b using NdeI/SalI to produce a noncleavable C-terminal His-
tagged construct. For FRET studies, p97 coding sequences were amplified by
PCR and ligated into a modified pET28a vector to produce a construct with a
noncleavable C-terminal His-tag and an N-terminal ybbR tag with a short linker
(MDSLEFIASKLAGGGS). The construct for full-length p47 with a noncleavable
N-terminal His-tag (80) was obtained through Addgene (#21268), and site-directed
mutagenesis was used to make a p47-Thr370Cys mutation. Proteins were expressed
and purified as described previously (28), with the exception that p47 was expressed
in TOP10 cells for 3 h at 37 °C. For FRET, p47-Thr370Cys was incubated with
tetramethylrhodamine-5-maleimide (ThermoFisher) prior to gel filtration to produce
p47TAMRA. For ybbR labeling, Cy5-CoA conjugate and Sfp enzyme were made as
19
described (132). Thirty micromolar ybbR-VCPwas incubated for at least 3 h at room
temperature with 60 µM Cy5-CoA conjugate and 12 µM Sfp in 50 mM HEPES pH
7.4, 10 mM MgCl2 prior to gel filtration. All proteins were purified on a Superose
6 gel filtration column.
UN FRET reagents
AnN-terminal sortase recognition motif was added to the N-terminus of Npl4
(50) to formMGGG-Npl4. To prevent labeling of His-Ufd1 (125), site directed mu-
tagenesis was used to remove residue G2. This modified UN was expressed and
purified as previously described (141) with one modification. Prior to gel filtration,
30 µM UN was labeled using 500 µM peptide (TRITCWSHPQFEKLPETGG, Gen-
Script) and 5 µM sortase (135) in labeling buffer (25 mM Hepes pH 7.4, 150 mM
NaCl, 10 mM CaCl2, 1 mM DTT) at 25 °C for 2 hours. The reaction was diluted in
Strep-tag buffer (100 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA) and incubated
with 2 mL of Strep-Tactin resin (IBA Lifesciences) for 10 minutes at 4 °C with
agitation. Resin was washed with 5 column volumes of Strep-tag buffer and eluted
with Strep-tag buffer plus 50 mM biotin.
Mixed hexamer preparation
A plasmid for co-expression of p97 and p97-A232E-His was constructed
via Gibson cloning to insert sequences from p97-His and p97-A232E-His into a
pCOLA-Duet backbone. Protein was expressed in Rosetta DE3 overnight at 16 °C
overnight with 0.4 mM IPTG. Cell pellet was resuspended in nickel binding buffer
(50 mM Tris pH 7.4, 500 mM KCl, 5 mM MgCl2, 20 mM imidazole, 5% glycerol,
2 mM β-mercaptoethanol) with protease inhibitors and sonicated. Clarified lysate
was bound to a HisTrapHP (GEHealthcare) and eluted in a stepwise gradient of 12%
(wash), 20% (’Mixed 1’), 35% (’Mixed 2’), and 55% (’Mixed 3’) nickel binding
buffer with 300 mM imidazole. Proteins were purified on a Superose 6 column (GE
Healthcare) in storage buffer (20 mM Hepes pH 7.4, 250 mM KCl, 1 mM MgCl2,
5% glycerol, 0.5 mM TCEP), concentrated, and flash frozen.
p97-p47 FRET measurements
All FRET measurements were carried out in 20 mM Hepes, pH 7.4, 100 mM
KCl, 3 mM MgCl2, 1 mM TCEP, and 1 mg/ml ovalbumin (Sigma). Nucleotides
were optionally present at 2 mM, and inhibitors were optionally present at 15 µM.
Equilibrium binding assays were carried out on a FluoroLog-3 (Jobin Yvon), with
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excitation at 540 nm and emission scan 555–750 nm. Stopped-flow experiments
were carried out on a Kintek SF-300X instrument with excitation at 540 nm and a
580/20 emission filter. Data were analyzed using Prism 6 (GraphPad).
p97-UN FRET measurements
Assays were carried out at room temperature in assay buffer (20 mM Hepes
pH 7.4, 150 mM KCl, 20 mM MgCl2, 1 mM TCEP, 1 mg/mL bovine serum al-
bumin (BSA)) supplemented with 2mM ADP, 2 mM ATPγS, or ATP regeneration
system (5 mMATP, 30 mM creatine phosphate, 50 µg/mL creatine phosphokinase).
Equilibrium binding assays were measured on a fluorometer (Photon Technology In-
ternational, Inc) with 50 nMUTRIRCN. Data were fit to a parabolic binding equation.
Kinetic constants were measured using an AutoSF-120 stopped flow fluorimeter
(KinTek) with an excitation wavelength of 540 nm and an emission filter of 576 ±
31 nm. For measurements of kon, the final concentrations were 50 nM UTRITCN
and 50-400 nM Cy5p97. Data were fit to single exponential decay equation to fit
kobs, and linear regression of kobs versus [Cy5p97] were used to calculate kon. For
measurements of koff, 100 nM UTRITCN and 500 nM Cy5p97 were incubated before
mixing with 5 µM UN (final dilution 2X). Data were fit to a single exponential
association equation to extract koff. For competition FRET experiments, final con-
centrations were 25 nM UTRITCN, 25 nM Cy5p97-A232E, and various values of
unlabeled p97 protein. Fluorescence intensity was measured on a Synergy Neo2
plate reader (BioTek) using a 540 nm excitation filter and 590 nm emission filter.
FRET efficiencies were calculated from a control UTRITCN sample, and percent
inhibition was calculated relative to a UTRITCN-Cy5p97-A232E sample. Inhibition
curves were fit to an IC50 equation, and Ki was calculated using the known KD of
UTRITCN-Cy5p97-A232E and protein concentrations.
Protomer exchange assay
Aplasmid encoding p97-FLAG for bacterial expression wasmade through the
addition of a FLAG tag to a plasmid encoding untagged p97 in a pET24b backbone
(RDB#3376). Protein was expressed in Rosetta DE3 as previously described (141).
Harvested cells were resuspended in lysis buffer (50mMTris pH 7.4, 150mMKCl, 5
mMMgCl2, 5% glycerol) with protease inhibitors (Roche) and sonicated. Clarified
lysate was incubated with 1 mL anti-FLAG resin (Sigma) at 4 °C for 1 hour. Resin
was washed with 3 column volumes of wash buffer (50 mM Tris pH 7.4, 400 mM
KCl, 5 mM MgCl2, 0.5% Triton X-100) three times for ten minutes with rotation
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followed by one wash with elution buffer without FLAG peptide (25 mM Hepes pH
7.4, 150 mM KCl, 2 mM MgCl2). Protein was eluted with 2 mL of elution buffer
containing 0.2 mg/mL 3XFLAG peptide for ten minutes with rotation. Elution was
repeated, and resin was drained with a final 2 mL of elution buffer. After elution,
concentrated protein was purified by gel filtration (Superose 6) in storage buffer (20
mMHepes pH 7.4, 250 mMKCl, 1 mMMgCl2, 5% glycerol, 0.5 mMTCEP) before
flash freezing.
A solution of 250 nM of Cy5p97-His with or without 250 nM p97-FLAG was
incubated for ten minutes at 25 °C with 25 µL anti-FLAG resin (Sigma) in 100
µL exchange buffer (50 mM Tris pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.01%
Triton X-100, ATP regeneration system). Resin was washed three times with 500
µL of exchange buffer without ATP regeneration system, and resin was boiled in
SDS-PAGE sample buffer to elute. Samples were run on a 7% SDS-PAGE gel and
imaged on a ChemiDoc (BioRad).
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C h a p t e r 3
IN VITRO RECONSTITUTION OF P97 UNFOLDASE ACTIVITY
The entirety of this chapter was originally published in: Blythe, E.E., Olson, K.C.,
Chau, V., Deshaies, R.J. (2017) Ubiquitin- and ATP-dependent unfoldase activity
of p97/VCP •NPLOC4 •UFD1L is enhanced by a mutation that causes multisystem
proteinopathy. Proc. Natl. Acad. Sci. USA 114, E4380-E4388.
3.1 Introduction
The commonmechanism that underlies all of p97’s cellular jobs is presumed to
be the extraction and unfolding of ubiquitylated proteins (21, 142). The nature of the
majority of known p97 substrates—unstable, scarce, modified by ubiquitin, and not
readily divorced from their contexts—presents challenges for studying the enzymatic
activity of p97 in a systematic manner. A major barrier to progress has been the
absence of a simple, rapid, quantitative assay using defined components, that can
be employed to dissect in detail the mechanism of action of p97. To address this
obstacle, we have developed a soluble, monomeric p97 substrate. Our substrate is
based on a non-cleavable ubiquitin fusion protein, UbG76VGFP, which is targeted for
proteolysis by the Ub fusion degradation (UFD) pathway (143). Normally, ubiquitin
fusions are co-translationally cleaved by a deubiquitinating enzyme to remove the
ubiquitin (144). However, if the C-terminal glycine ismutated, processing is blocked
and the fusion is rapidly degraded. Previous studies have demonstrated that the
degradation of these non-cleavable Ub fusion proteins, including UbG76VGFP, is
dependent upon p97•UN in human, Drosophila, and yeast cells (34, 98, 143, 145).
We show that p97 can unfold UbG76VGFPmodified with a K48-linked polyUb chain
and that this reaction is dependent upon the nature of the Ub chain, UN, and p97
ATPase activity in D2. Our system provides the first direct demonstration of a p97
unfoldase activity that depends on predicted physiological requirements and will be
an invaluable tool for further study of p97 mechanism.
3.2 Results
Substrate and Assay Design.
We chose to pursue the UFD pathway substrate UbG76VGFP because it is
rapidly degraded in a p97-dependent manner in yeast, Drosophila, and human cells
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(34) and is a well-behaved protein whose folding state can be easily monitored
by fluorescence. As p97 substrates are often polyubiquitylated, and p97•UN binds
polyubiquitin (33), we reasoned that UbG76VGFPwould need to be polyubiquitylated
to be recognized. To efficiently ubiquitylate it, we developed a chimera of the RING
domain from the E3 ubiquitin ligase gp78 and the E2 enzyme Ube2g2. Prior studies
have shown that these enzymes catalyze formation of K48-linked ubiquitin chains
(33). Notably, these two enzymes function upstream of p97 in ERAD, attesting to the
physiological relevance of the use of these enzymes to generate a p97 substrate for
our assay (146, 147). Compared with Ube2g2 alone or unfused Ube2g2 with added
gp78RING (Figure 3.1A), the gp78RING-Ube2g2 chimera produced unanchored
polyubiquitin chains with very high efficiency (Figure 3.1B).
Figure 3.1: Characterization
of gp78RING-Ube2g2 chimera.
Time-courses comparing the rate
of ubiquitin polymerization by
0.1 µM Ube2g2 alone or in the
presence of 20 µM gp78RING
(A), or when Ube2g2 is fused di-
rectly to gp78RING (B; assayed at
0.1 µM). The chimera is >6-fold
faster than the unfused proteins.
Using this tool, we used various strategies to produce three types of potential
p97 substrates. To simplify notation, linearly fused proteins are shown by dashes,
and the length of the K48-linked ubiquitin chain attached to a particular ubiquitin
is shown with a superscript preceding the initiator ubiquitin. First, we aimed
to create a substrate with a short ubiquitin chain of defined length. Although
the minimal requirement for recognition of ubiquitylated proteins by p97 is not
known, the minimum ubiquitin chain length for recognition by the proteasome
is four (8). Therefore, we enzymatically ligated Ub3, in which the ubiquitins
were joined via K48 linkages and the distal ubiquitin carried a K48R mutation,
onto the linearly fused ubiquitin to form pure Ub3Ub-GFP (Figure 3.2A) (148,
149). Second, to create a substrate with longer polyubiquitin chains, we built K48-
linked chains directly onto the linearly fused ubiquitin (Figure 3.2B). Finally, to
produce substrate with branched ubiquitin chains, we built ubiquitin chains on a
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base substrate containing two or more linearly fused ubiquitins (Ub-Ub-GFP or
Ub-Ub-Ub-GFP; Figure 3.2C). Heterogeneous substrates were fractionated by size-
exclusion chromatography to enrich for different chain lengths (Figure 3.2D). One
concern we had was the potential for GFP to refold after being processed by p97,
leaving the assay without an observable endpoint. To address this, we added an
ATPase mutant of the chaperonin GroEL. The GroEL D87K “trap” retains the
ability to bind unfolded proteins but can no longer release those proteins (150). This
dead-end complex sequesters unfolded GFP, preventing it from refolding, and has
been used previously to provide assay endpoints for other unfolding machines (88).
GFP is unfolded by p97 in an Ub- and UN-dependent manner
To explore the unfolding potential of p97, we first compared a set of Ub-
GFP substrates bearing K48-linked ubiquitin chains of varying lengths (Figure
3.4A). When mixed with p97, UN, and GroEL (Figure 3.2), Ub-GFP and Ub3Ub-
GFP showed no appreciable loss of GFP fluorescence (Figure 3.4B). However, Ub-
GFP with both “medium” (>4 Ub, UbMUb-GFP) and “long” (>12 Ub, UbLUb-GFP)
ubiquitin chains showed a modest decrease in fluorescence over time ( 30%, Figure
3.4). Whereas UbLUb-GFP did show improved unfolding relative to UbMUb-GFP,
the difference was quite small ( 5% signal loss).
We examined further the requirements for p97-dependent unfolding using
UbLUb-GFP, since this substrate gave the largest signal. When incubated with only
p97 or p97 and GroEL, no unfolding was observed (Figure 3.4C). A similar result
was obtained when UN was replaced with p47 or UBXD7, p97 adaptors involved in
Golgi reassembly after mitosis (63) and regulation of cullin-RING Ub ligases (49,
60, 151), respectively, despite both of these adaptors binding to p97 and substrate
(Figure 3.5). Therefore, UN is required for p97-catalyzed unfolding, and it cannot
be replaced by other adaptors. Additionally, GroEL was essential to provide an
endpoint for the assay. Fluorescence loss was amplified by the addition of GroEL
(Figure 3.4C), indicating GFP was able to refold to some degree after processing
by p97•UN. However, GroEL did not unfold substrate on its own (Figure 3.4C),
and immunoprecipitation of GroEL showed that p97•UN was required for GroEL
interaction with substrate (Figure 3.4D). Unfolding of substrate by p97 was also
highly temperature dependent, with the rate and extent of unfolding increasing
between 22-42 °C (Figure 3.6).
We found it curious that ≤40% of the fluorescence signal of UbLUb-GFP was
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Figure 3.2: Substrate design and synthesis. (A) Preassembled, K48-linked Ub3 chains containing a K48R
mutation on the distal ubiquitin were ligated onto a noncleavable linear His6-Ub-GFP fusion protein to produce
pure Ub3Ub-GFP. (B) E1, E2, ubiquitin, and ATP were added to His6-Ub-GFP to elongate K48-linked ubiquitin
chains of varying lengths on the ubiquitin fused to GFP. These resulting substrates were purified from free
ubiquitin chains via Ni-NTA resin and crudely fractionated according to chain length via size-exclusion chro-
matography to produce pools of “long-”, “medium-”, and “short”-chain substrates (UbLUb-GFP, UbMUb-GFP,
and UbSUb-GFP, respectively). (C) To produce branched chains, ubiquitin chains of varying length were enzy-
matically elongated on a di- or triubiquitin linear fusion protein, Ub-Ub-GFP, or Ub-Ub-Ub-GFP, similar to B.
(D) Size-exclusion chromatogram and corresponding SDS/PAGE gel for the purification of substrate described
in B.
typically lost in our unfolding assays even though all components of the system
were at or very near saturation (Figure 3.7), suggesting that there was another
factor influencing substrate competence that remained to be discovered. Three Ub
binding sites with different chain linkage preferences are available on p97•UN (33).
Therefore, we tested whether substrates carrying branched Ub chains would be more
effectively unfolded, because a branch would enable two separate ubiquitin chains to
be elaborated from a single attachment point (in this case, Met1 of GFP). As a proxy
for Ub chains with branched linkages, we expressed Ub-GFP fused to one or more
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Figure 3.3: SDS-PAGE analysis of proteins used in this study.
additional ubiquitins in tandem and used these proteins as substrates for subsequent
enzymatic polyubiquitylation (Figure 3.8A). Interestingly, a substrate in which K48-
linked polyubiquitin chainswere polymerized onUb-Ub-GFP (UbMUb-UbMUb-GFP)
showed significant improvement in unfolding by p97 as compared to UbMUb-GFP
(Figure 3.8B) despite the latter having a greater amount of ubiquitin conjugation as
judged by mobility upon SDS-PAGE (Figure 3.8A, lanes 1 and 2). Neither further
extension of the chains to form UbLUb-UbLUb-GFP nor use of a triubiquitin fusion
significantly increased the rate or extent of unfolding (Figure 3.8B). Although we
cannot directly visualize ubiquitin chains branching from each ubiquitin in the Ub-
Ub-GFP fusion protein, reactions run with Ub-K48R indicate that both Ub moieties
were efficiently conjugatedwith ubiquitin under our reaction conditions (Figure 3.9).
Incidentally, this same reaction confirms the linkage specificity of our Ube2g2–gp78
E2–E3 chimera. Taken together, our data suggest that the physical arrangement of
the Ub chains is important for unfolding by p97•UN, with the enzyme preferring
substrates with at least one branch point that enables nucleation of more than one
chain of K48-linked ubiquitins.
Substrate unfolding is dependent upon ATP hydrolysis and stimulates p97
ATPase activity
Nextwe examined the energy-dependence of p97-catalyzed unfolding. UbLUb-
UbLUb-GFP was not unfolded by p97 in the absence of nucleotide, and ADP or the
nonhydrolyzable ATP analog ATPγS could not substitute for ATP (Figure 3.10A).
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Figure 3.4: p97 unfolds Ub-GFP in a UN-dependent manner.(A) SDS/PAGE analysis of GFP substrates with
different ubiquitin chain structures stained with Coomassie Brilliant Blue. (B) Upon addition of ATP, 75 nM
p97, 150 nM UN, and 250 nM GroEL, 25 nM Ub-GFP, and Ub3-GFP did not appreciably lose fluorescence over
time. However, Ub-GFP with “medium” or “long” K48-linked chains (UbMUb-GFP and UbLUb-GFP) exhibited
26% and 32% loss of signal after 15 min, respectively. Representative traces shown (n ≥ 3). (C) Fluorescence
of UbLUb-GFP did not change over time with the addition of p97, GroEL, or p97 plus GroEL. Upon addition
of p97 plus UN, a small decrease in signal was observed, and this decrease was augmented with the addition of
GroEL. Representative traces shown (n ≥ 2). (D) UbLUb-GFP coimmunoprecipitated with GroEL only in the
presence of p97 and UN.
Two p97 ATPase inhibitors, the allosteric inhibitor NMS-873 (14) and the D2-
specific, ATP-competitive inhibitor CB-5083 (15), also prevented ATP-dependent
substrate processing (Figure 3.10A). p97with a D1 domainWalker Bmotif mutation
(p97-E305Q) that blocks nucleotide hydrolysis but not binding exhibited only mild
defects in substrate unfolding. By contrast, the same mutation in D2 (p97-E578Q)
completely abolished unfoldase activity (Figure 3.10B; Table 3.1). Together, these
data demonstrate that ATP hydrolysis in D2 powers the unfolding of substrate by
p97•UN.
Some adaptors modulate p97 ATPase activity (79), so we examined the effects
of substrate processing on the hydrolysis of ATP by p97 and p97•UN. Addition of
long unanchored K48-linked ubiquitin chains (UbLUb), Ub-GFP, Ub3Ub-GFP or
UbLUb-UbLUb-GFP did not alter the ATPase activity of p97 (Figure 3.11). Whereas
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Figure 3.5: p97 adaptors p47 and UBXD7
do not promote substrate processing. (A)
In the presence of p97 and GroEL, UN pro-
moted a decrease in fluorescence of UbLUb-
UbLUb-GFP, indicating substrate unfolding.
However, p47 and UBXD7 were not able to
replace UN. Representative traces shown, n
≥ 2. (B) Both p47 and UBXD7 bind UbLUb-
UbLUb-GFP and mediate its interaction with
p97, as shown by co-immunoprecipitation
with purified proteins. Reactions contained
100 nM p97, 200 nM adaptor, and 200 nM
substrate and were immunoprecipitated with
antibodies to either GFP or p97, as indicated.
Figure 3.6: Unfolding by p97 is tempera-
ture dependent. Unfolding reactions using
UbLUb-UbLUb-GFP were carried out at 22
°C, 37 °C, and 42 °C.Higher temperatures in-
creased both the rate and extent of the unfold-
ing reaction. Representative traces shown, n
≥ 2.
Figure 3.7: Unfolding reaction components
are saturating. (A) When the concentra-
tion of GroEL was halved or the concentra-
tion of UN was doubled, minimal changes
in the rate of unfolding of UbLUb-UbLUb-
GFP were observed. Representative traces
shown, n = 2. (B) When the concentration of
p97 was doubled, virtually no change in the
rate of unfolding of UbLUb-UbLUb-GFP was
observed. Representative traces shown, n =
2.
UN did not significantly affect the ATPase activity of p97, the further addition of
UbLUb-UbLUb-GFP stimulated ATP hydrolysis by 4-fold, whereas Ub-GFP and
Ub3Ub-GFP had no effect (Figure 3.10C). The latter result is consistent with the
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Figure 3.8: Branched ubiquitin chains are better p97 substrates. (A) SDS/PAGE analysis of Ub-GFP substrates
stained with Coomassie Brilliant Blue. (B) Comparison of unfolding of substrates with one, two, or three
ubiquitins fused in tandem to GFP. Note that substrate with two linearly fused ubiquitins (e.g., UbMUb-
UbMUb-GFP) was unfolded to a greater extent by p97 than substrate with a single linearly fused ubiquitin
even though aggregate ubiquitination for the latter substrate was at least as extensive or greater than the former.
Addition of an additional linearly fused ubiquitin (UbLUb-UbLUb-UbLUb–GFP) yielded no further improvement.
Representative traces shown (n ≥ 3).
Figure 3.9: Two Ub-K48R can be added onto
Ub-Ub-GFP. Time course of reaction of 10 µM
Ub-Ub-GFP with 200 µM Ub-K48R under con-
ditions identical to those used to make substrate
produced pure Ub1Ub-Ub1Ub-GFP, indicating that
Ub chains are assembled on both fused ubiquitins
in Ub-Ub-GFP. SDS-PAGE analysis of unboiled
samples. GFP detected by excitation at 488 nm.
Mutant Rate, min-1 Plateau, % n
WT 0.195 ± 0.007 33.3 ± 0.8 6
E305Q 0.154 ± 0.005 36.5 ± 0.8 3
E578Q ND ND 3
A232E 0.274 ± 0.007 25.3 ± 0.4 3
Table 3.1: Rates and extents of unfolding of UbLUb-UbLUb-GFP by p97 mutants. The rates and plateaus
were calculated by fitting data to a single exponential decay, with the plateau representing the percentage of
fluorescence remaining at the end of the reaction. Unpaired t tests comparing WT rates vs. those of p97-E305Q
and p97-A232E yielded P values of < 0.0001 in both cases, indicating statistically significant differences.
Sample size represents number of technical replicates, and values are shown ± SD. ND, not detected.
inability of p97•UN to unfold Ub-GFP or Ub3Ub-GFP. Neither p47 nor UBXD7
supported substrate-triggered acceleration of p97 ATP hydrolysis (Figure 3.11B).
Long, unanchored Ub chains also stimulated p97 ATPase activity to a similar degree
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Figure 3.10: ATPase activity of p97 is critical for and stimulated by substrate unfolding. (A) Fluorescence
traces of UbLUb-UbLUb-GFP in the presence of p97, UN, GroEL, and various nucleotides and p97 inhibitors.
Unfolding was observed only in the presence of ATP. Representative traces shown (n ≥ 2). (B) Unfolding of
UbLUb-UbLUb-GFP by p97 ATPase mutants. p97-E305Q and p97-E578Q are deficient in D1 and D2 ATPase
activity, respectively. p97-E305Q was able to unfold substrate, whereas p97-E578Q was not. Representative
traces shown (n ≥ 3). (C) Substrate stimulates ATPase activity of p97whenUN is present. Unanchored ubiquitin
chains and those linked to Ub-GFP yielded equivalent stimulation, whereas Ub-GFP and Ub3Ub-GFP did not
stimulate. ATPase activity was measured with BIOMOL Green as described in Methods and was normalized
to basal WT p97 activity. Error bars represent SD (n = 4). (D) Effect of substrate plus UN on ATPase activity
of D1 and D2 domain ATPase mutants. Addition of UbLUb-UbLUb-GFP plus UN slightly decreased ATPase
activities of D1 mutant E305Q and D2 mutant E578Q. Error bars represent SD (n = 4).
as UbLUb-UbLUb-GFP, suggesting that p97 interaction with Ub chains and not the
GFP substrate itself was both necessary and sufficient for the observed acceleration.
In agreement with the unfolding results, the residual ATPase activity of p97-E578Q
was unaffected by substrate plus UN (Figure 3.10D). However, p97-E305Q, which
was able to unfold substrate, was also not stimulated by substrate, even showing a
slight decrease in ATPase activity (Figure 3.10D). The E305Q mutant also showed
higher basal ATPase activity than WT, as has been seen before in steady-state
experiments (28). These results suggest that there is a high degree of crosstalk
between ATPase activity in D1 and D2, and whereas ATP hydrolysis in D2 is the
driving force for unfolding, D1 activity is also needed for substrate-induced ATPase
acceleration.
UN recruits substrate to p97
The tight correlation between the competence of a substrate to be unfolded
and its ability to accelerate ATP hydrolysis suggests that binding of substrate to p97
may stimulate ATPase activity, leading to substrate unfolding. To further probe this
hypothesis, we evaluated binding of substrate to p97. Immunoprecipitation of p97
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Figure 3.11: Substrate alone or
in complex with other adaptors
does not accelerate p97 ATPase.
(A) ATPase activity of p97 is not
affected by substrate when UN
is absent. (B) p47 and UBXD7
do not promote substrate-induced
ATPase acceleration. Addition
of substrate did not significantly
change the ATPase activity of
p97•p47 or p97•UBXD7. AT-
Pase activity was measured with
BioMol Green as described in
Methods. Error bars represent
S.D. with n = 4.
showed that it bound UbLUb-UbLUb-GFP substrate in the presence but not in the
absence of UN (Figure 3.12, lanes 4 and 5). Reciprocal immunoprecipitation of
GFP confirmed that substrate bound UN in the absence of p97 but did not bind p97
in the absence of UN (Figure 3.12). Furthermore, the interaction between p97 and
UN appeared to be stabilized by substrate binding (Figure 3.12, lanes 3 and 5). We
also analyzed substrate dependence of GroEL association with p97, but observed
high background binding to our beads even in the absence of antibody (lane 1). The
binding signal was increased in lanes 6 and 7, but this could be due to p97, which
in our experience is prone to exhibit non-specific binding.
Whereas the unfolding of substrate was highly dependent on ATP hydroly-
sis, substrate interaction with p97 was not. Immunoprecipitation of FLAG-UbLUb-
FLAG-UbLUb-GFP pulled down equal amounts of p97 in the absence of added nu-
cleotide and in the presence of ATP, ATPγS, ATP plus NMS-873, and ATP plus
CB-5083 (Figure 3.12). Therefore, p97 does not have to be actively remodeling
substrate in order to effectively form a tight complex. Loss of binding of p97, but
not UN, was seen only with added ADP, which could be due to the large conforma-
tional changes observed for p97 in its ADP-bound state (22) (Figure 3.12). These
results are consistent with previous studies on Ub chain association with p97 and
p97•UN (52, 152).
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Figure 3.12: UN recruits ubiquitylated substrate to p97. (A) Association of substrate with p97 depends on
UN. Reactions containing 100 nM p97, 200 nM UN, 200 nM UbLUb-UbLUb-GFP and/or 200 nM GroEL were
immunoprecipitated using an anti-p97 antibody and assessed by western blot. Substrate was pulled down with
p97 only in the presence of UN, and substrate enhanced the binding of UN to p97. Effects of substrate and
UN on binding of GroEL to p97 could not be determined due to high background binding of GroEL to beads,
antibody and/or p97. (B) UN binds directly to substrate and links it to p97. Samples prepared as in (A)
were immunoprecipitated with an anti-GFP antibody. Substrate pulled down UN but only bound p97 in the
presence of UN. (C) Bound nucleotide has only a modest effect on formation of a p97•UN•substrate ternary
complex. Samples prepared as in (A) with various nucleotides and/or p97 inhibitors were immunoprecipitated
by anti-FLAG resin, which bound the FLAG-tagged Ub on substrate. Binding of p97, but not UN, was reduced
only in the ADP state.
3.3 Discussion
P97/VCP is implicated in a broad range of cellular processes including mem-
brane fusion, protein trafficking, and ubiquitin dependent proteolysis (27). It is
thought that the core biochemical activity of p97 that enables its diverse biologi-
cal functions is its ability to act as a segregase that segregates polypeptides from
binding partners in multisubunit complexes, or from large macromolecular struc-
tures including ribosomes, membranes, or chromatin. Although the mechanism by
which p97 exerts segregase activity is not known, the most economical hypothesis
is that it grabs onto the polypeptide to be segregated and commences to unfold it.
However, despite the appeal of this unifying hypothesis, the ability of WT p97 to
harvest the energy of ATP hydrolysis to unfold a polypeptide has never been directly
demonstrated. We show here, in a well-defined system, that WT p97 can at least
partially unfold a protein. In contrast to prior studies that used a doubly mutated
p97 acting upon an unmodified protein in the absence of any adaptor (153, 154),
the unfolding we observe exhibits dependencies predicted from prior genetic and
biochemical studies of p97, including dependence on ATP hydrolysis by the D2 AT-
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Pase domain of p97, the heterodimeric adaptor NPLOC4•UFD1L, and conjugation
of an ubiquitin chain to the substrate that is unfolded (27, 32, 33).
Despite the close alignment of in vitro dependencies reported herewith known
in vivo requirements for p97 action, there are two caveats worth noting. First, we do
not know whether the loss of GFP fluorescence is the result of complete unfolding
or local unfolding. Second, our Ub-GFP model substrate is not a native substrate
of p97. However, p97 activity in the UFD pathway is absolutely required for its
degradation in vivo in yeast, Drosophila, and human cells (34, 98, 143, 145), and
the E2–E3 chimera used to ubiquitylate Ub-GFP was derived from enzymes that
function directly upstream of p97 in the ERAD pathway (146). Thus, we believe
the reaction reported here represents the essence of p97’s biochemical activity that
underlies its physiological functions.
Processing of our Ub-GFP substrate by p97 is dependent on the conjugation
of multiple ubiquitins connected by K48 linkages, which is consistent with reports
of K48-linked ubiquitin chain binding by p97 and UFD1L and linkage-nonspecific
chain binding by NPLOC4 (33, 52, 77, 152). One of our most interesting findings
is that we observed enhanced substrate unfolding when the substrate contained a
branch point enabling the formation of multiple K48-linked ubiquitin chains. Our
substrate contains a branch at the base of the ubiquitin conjugate, which allows for
two K48-linked chains to be built on a single site of substrate modification. Because
there are multiple ubiquitin binding sites on the p97•UN complex, the branched
chain on our UbLUb-UbLUb-GFP substrate may retard, via enhanced avidity, its
dissociation before unfolding. Branched ubiquitin chains can enhance substrate
degradation (102) and have been associated with p97 previously. Ubiquitin chains
with K11 linkages are associated with multiple p97 adaptor proteins (49) and are
implicated in ERAD (155). Substrates modified with K11 and K11–K48 branched
chains associate with p97•UN and its Drosophila ortholog (134, 156), and p97
binds K11–K48 branched chains better than either type of homotypic chain (102).
Furthermore, K29 and K48 linkages are formed on UFD pathway substrates in
vivo and in vitro using purified UFD pathway enzymes (98, 101). Whereas our
data with linear ubiquitin fusions suggest that branched and/or multiple ubiquitin
chains may be important for interaction of substrates with p97•UN, further work
with physiological linkages in vitro and in vivo is needed to determine the exact
requirements for ubquitylated p97 substrates.
The second requirement for p97-catalyzed unfolding is the heterodimeric
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adaptor UN. In agreement with prior work, UN bridges the interaction of substrates
with p97 (33, 52). However, p97 also associates with other adaptor proteins, some
of which (e.g., UBXD7) can cobind with UN and others (e.g., p47) of which
bind in a mutually exclusive manner (49, 51, 65, 66, 71). Although there are
examples of processes that require UN and an additional adaptor (59, 157), in
general, it is unclear whether the different adaptors work in different pathways, or
work sequentially, together, or in opposition to one another in the same pathway.
Mutually exclusive adaptors like p47 bind very differently fromUN yet also promote
protein segregation (63, 76, 78). However, neither p47 nor UBXD7 was able to
replace UN in our unfolding assay, suggesting they promote substrate processing in
a different way or work on different substrates. Our assay provides the first platform
for further mechanistic exploration of the functional relationship between different
adaptor proteins.
The final requirement for unfolding of GFP is ATP hydrolysis by the D2
ATPase of p97. Our results are in direct contrast with a previous studywhich showed
that p97-dependent unfolding is inhibited by ATP (158), but are consistent with
overwhelming in vitro and in vivo data (27, 33, 35, 95). Our experiments with p97
mutants and the D2-specific ATP-competitive inhibitor CB-5083 demonstrate the
importance ofD2ATPase activity over that ofD1, which confirms prior observations
(28–30, 32–35). We observed very little effect of the D1 Walker B mutant on
substrate processing, leaving the role of D1 ATPase activity in p97 function unclear
(27). Not only is the ATPase activity key to substrate processing but we also observe
its stimulation by Ub chain or substrate binding. This stimulation was abolished in
the D1 Walker B mutant. Nevertheless, this mutant unfolded GFP at near-WT rates,
suggesting that substrate stimulation of ATP hydrolysis might not be essential, at
least for some substrates. ATPase acceleration in the presence of the cytoplasmic
fragment of the ERAD substrate Sytl has been previously reported, but unlike the
stimulation reported here, it was not dependent upon UN or ubiquitylation of the
substrate (95), both of which are thought to be requirements for ERAD. p97 can
interact both with a substrate and the Ub chain appended to the substrate (33, 159),
suggesting that stimulation of p97 ATPase and perhaps substrate processing can be
regulated through multiple binding interfaces.
35
3.4 Methods
Protein and expression purification
Adescription of the construction, expression and purification of novel reagents
is described below. A description of previously published proteins used in this study
can be found in Table 3.2.
RDB
Num-
ber
Plasmid
name Vector Expression Purification Comments Ref.
3019 Ube1 pET28b BL21, 0.5 mM IPTG,16 °C for 16 hours Ni-NTA, S200 (160)
2804 Cdc34 pGEX-6P-1
BL21, 0.4 mM IPTG,
25 °C for 16 hours
Glutathione sepharose,
S200 (148)
3166 gp78-Ube2g2 pET28a
BL21, 0.4 mM IPTG,
25 °C for 16 hours
Ni-NTA, S75, TEV
cleavage, MonoQ
This
study
2805 His-Ub pET15b BL21, 0.4 mM IPTG,16 °C for 16 hours
Ni-NTA, thrombin
cleavage, S75 (148)
3348 His-Ub-K48R pET15b
BL21, 0.4 mM IPTG,
16 °C for 16 hours
Ni-NTA, thrombin
cleavage, S75
This
study
3006 His-Ub-G76V-GFP pET28a
BL21, 0.4 mM IPTG,
37 °C for 4 hours Ni-NTA, S200
This
study
3344 His-Ub2-G76V-GFP pET28a
BL21, 0.4 mM IPTG,
37 °C for 4 hours Ni-NTA, S200
This
study
3345 His-Ub3-G76V-GFP pET28a
BL21, 0.4 mM IPTG,
37 °C for 4 hours Ni-NTA, S200
This
study
3219 p97-His pET24b Rosetta, 0.1 mM IPTG,25 °C for 16 hours Ni-NTA, S6 (87)
3346 p97-HisE305Q pET24b
Rosetta, 0.1 mM IPTG,
25 °C for 16 hours Ni-NTA, S6
This
study
3347 p97-HisE578Q pET24b
Rosetta, 0.1 mM IPTG,
25 °C for 16 hours Ni-NTA, S6
This
study
3352 p97-HisA232E pET24b
Rosetta, 0.1 mM IPTG,
25 °C for 16 hours Ni-NTA, S6
This
study
2686 NPLOC4 pCOLA-Duet
BL21, 0.4 mM IPTG,
16 °C for 16 hours Ni-NTA, S200
Co-purified
with UFD1L (50)
2796 His-UFD1L pET28a BL21, 0.4 mM IPTG,16 °C for 16 hours Ni-NTA, S200
Co-purified
with NPLOC4 (125)
2886 His-p47 pTrcHis TOP10, 0.4 mM IPTG,37 °C for 4 hours Ni-NTA, S200 (80)
2598 GST-FLAG-UBXD7
pGEX-4T-
2-TEV
Rosetta, 0.4 mM IPTG,
37 °C for 4 hours
Glutathione sepharose,
TEV cleavage, S200 (60)
3218 GroELD87K T7
TOP10 0.4 mM IPTG,
37 °C for 4 hours
HiTrap Q FF, S6,
Affigel Blue (150)
Table 3.2: Proteins used in this study.
gp78RING-Ube2g2 chimera construction and purification
A72-residue sequence of theE3ubiquitin protein ligase gp78/AMFR (residues
322 to 393), containing the RING domain, was fused to the N-terminus of the
ubiquitin-conjugating enzyme Ube2g2 with a linker sequence of GTGSH. cDNA
encoding this fusion protein was inserted into the bacterial expression plasmid
36
p28a-TEV vector to encode a polyHis-tagged protein. Protein was expressed in
BL21(DE3) at 37 °C with 0.4 mM IPTG for 4 hours and was purified on Ni-NTA
resin and a Superdex 75 column before being cleaved with TEV protease overnight
at 4 °C. Cleaved protein was then bound to a MonoQ ion exchange column, eluted
with a NaCl gradient (0.05 – 0.5 M), concentrated with centrifugal filter units, and
flash frozen.
UbG76VGFP fusion construction
The coding sequence for UbG76VGFP in the EGFP-N1 vector (RDB# 1832)
(34) was PCR amplified and inserted into pET28a using NdeI and NotI sites to
produce His6-UbG76V-GFP (RDB# 3006). His6-UbG76V- UbG76V-GFP (RDB#
3344) and His6-UbG76V-UbG76V-UbG76V-GFP (RDB# 3345) were created by lig-
ating Ub2G76V and Ub3G76V, PCR amplified from a synthetic Ub4G76V sequence
(RDB# 2406), into His-UbG76V-GFP cut with NdeI and HindIII. For simplification,
the G76V notation has been left out of subsequent mentions of these constructs.
Ub3Ub-GFP synthesis and purification
A plasmid for bacterial expression of Ub-K48R (RDB# 3348) was made
from that of Ub (RDB# 2805) by site-directed mutagenesis, and the protein was
expressed as previously described (148). Pure K48-linked Ub3 chains carrying a
K48R mutation in the distal Ub were enzymatically synthesized and purified as
described previously (148, 149). To form Ub3Ub-GFP, 0.5 µM Ube1 (E1), 5 µM
gp78RING-Ube2g2, 2.5 µM Ub-GFP, and 5 µM Ub3 were incubated in 20 mM
Hepes pH 7.4, 5 mM ATP, and 5 mM MgCl2 overnight at 37 °C. The Ub3Ub-GFP
was then purified on Ni-NTA resin and a Superdex 200 gel filtration column before
being concentrated with centrifugal filter units and flash frozen.
Polyubiquitylated substrate synthesis and purification
Reactions were carried out with final concentrations of 10 µMUb-GFP fusion
protein, 1 µM E1, 20 µM gp78RING-Ube2g2, and 400 µM ubiquitin in 20 mM
Hepes pH 7.4, 10 mM ATP, and 10 mM MgCl2 at 37 °C overnight. Ubiquitin
was added progressively in small amounts over the first eight hours of the reaction.
For FLAG-tagged substrate, 40 µMFLAG-Ubiquitin (Boston Biochem, Cambridge,
MA, USA) was added in the first two hours. To purify ubiquitylated GFP from free
ubiquitin chains, the reaction mixture was incubated with Ni-NTA resin, eluted with
300 mM imidazole, and run over a Superose 6 size exclusion column in 20 mM
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Hepes, pH 7.4, 250mMKCl, 1mMMgCl2, 1 mMTCEP and 5% glycerol. Fractions
were pooled into long, medium, and short chain length samples, concentrated with
centrifugal filter units, and flash frozen.
ATPase assays
The ATPase assay protocol was modified from previously published meth-
ods (47). In an untreated microplate (#655101, Greiner Bio-One, Kremsmünster,
Austria), 40 µL solutions containing 30 nM p97 hexamer, 150 nM adaptor, and/or
150 nM substrate in ATPase assay buffer (25 mM Hepes pH 7.4, 100 mM KCl, 3
mM MgCl2, 1 mM TCEP, 0.1 mg/mL ovalbumin) were preincubated at 37 °C for
10 minutes. To this, 10 µL of a 1 mM ATP solution was added, and the reaction
was incubated at 37 °C for 5 or 10 minutes. After cooling on ice for 30 seconds, 50
µL of BIOMOL Green reagent (Enzo Life Sciences, Farmingdale, NY, USA) was
added. Solutions were developed at room temperature for 30 minutes before being
read at 600 nm. The amount of inorganic phosphate in each sample was calculated
from a standard curve, and relative ATPase activity for a sample was calculated by
normalizing its measurement to that of samples of WT p97 alone.
Fluorescence unfolding assays
Unless specified, all assays were carried out at 37 °C. Samples contained 25
nM GFP substrate, 75 nM p97 hexamer, 150 nM adaptor (UN, p47 or UBXD7),
and/or 250 nMGroEL trap in unfolding assay buffer (25 mMHepes pH 7.4, 100mM
KCl, 5 mM MgCl2, 1 mM TCEP, 2 mM ATP). Control experiments indicated that
the levels of p97, adaptor, and GroEL used were at or near saturation (Figure 3.7).
Other nucleotides and p97 inhibitors were present at 2 mM and 10 µM, respectively,
when indicated. Kinetic experiments were carried out on a Fluoro-Log 3 (Horiba
Jobin Yvon, Edison, NJ, USA) with excitation at 488 nm and emission at 509 nm.
Relative fluorescence was calculated by normalizing the fluorescence signal to that
at time zero. Unfolding rates were calculated by fitting curves to an exponential
decay model in Prism (GraphPad, San Diego, CA, USA).
Binding assays
Antibodies used for immunoprecipitation and western blotting are listed in
Table 3.3. Samples containing 100 nM p97, 200 nM UN, 200 nM GFP substrate,
and/or 200 nM GroEL trap in binding assay buffer (25 mM Hepes pH 7.4, 100 mM
KCl, 3 mMMgCl2, 1 mM TCEP) in a volume of 200 µL were preincubated at 37 °C
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for 15 minutes. Triton X-100 interfered with binding of substrate to GroEL trap, so
0.01% Triton X-100 was included in all buffers only in reactions that did not contain
GroEL. Nucleotides and inhibitors were present at 2 mM and 10 µM, respectively,
where indicated. For IPs using Protein G magnetic beads (Bio-Rad Laboratories,
Hercules, CA, USA), protein mixtures were incubated with 1 µL of antibody for
15 minutes at 37 °C prior to a 1 hour incubation with 25 µL of beads at room
temperature. For FLAG IPs, reactions were incubated with 25 µL of anti-FLAG
resin (Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes at room temperature.
Following incubation, all beadswerewashed 3 timeswith 750 µL assay buffer before
being boiled in 50 µL 2X SDS-PAGE loading dye. Samples were then analyzed by
western blot.
Purpose Antigen Source Species WB Titer
IP p97 ab11433, Abcam, Cambridge, UK mouse NA
IP GroEL gift from Arthur Horwich rabbit NA
IP GFP ab290, Abcam, Cambridge, UK rabbit NA
IP GFP Living Colors JL-8, Clontech Laboratories,Inc, Mountain View, CA, USA mouse NA
WB p97 ab11433, Abcam, Cambridge, UK mouse 1 : 2000
WB p97 H-120, Santa Cruz Biotechnology, Dallas,TX, USA rabbit 1 : 2000
WB UFD1L 611642, BD Biosciences, San Jose, CA,USA rabbit 1 : 500
WB UFD1L 13789, Cell Signaling Technologies,Danvers, MA USA mouse 1 : 1000
WB NPLOC4 13489, Cell Signaling Technologies,Danvers, MA USA mouse 1 : 1000
WB p47 sc134945, Santa Cruz Biotechnology,Dallas, TX, USA rabbit 1 : 200
WB UBXD7 AB10037, EMD Milliport, Billerica, MA,USA rabbit 1 : 1000
WB GFP Living Colors JL-8, Clontech Laboratories,Inc, Mountain View, CA, USA mouse 1 : 500
WB GFP ab290, Abcam, Cambridge, UK rabbit 1 : 1000
WB GroEL 82592, Abcam, Cambridge, UK mouse 1 : 1000
WB, HRP
conjugate rabbit IgG
170-6515, Bio-Rad Laboratories, Hercules,
CA, USA goat 1 : 10 000
WB, HRP
conjugate mouse IgG
115-055-174, Jackson ImmunoResearch,
West Grove, PA, USA goat 1 : 10 000
Table 3.3: Antibodies used in this study.
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C h a p t e r 4
P97 MSP MUTANTS ARE BETTER UNFOLDASES
4.1 Introduction
With an in vitro assay of p97 unfoldase activity in hand, we were interested
in directly assessing the effects of MSP mutants on this basic biochemical function
of p97 for the first time. Such an assay gives us the ability to begin to distinguish
between gain and loss of function models for MSP pathology. In our publication
discussed in the previous chapter, we began to address this by testing a single
MSP mutation, A232E, which is reported to have the most severe clinical MSP
presentation (81). Under single turnover conditions, A232E showed accelerated
unfolding compared to WT, indicative of a true gain of function (141). Importantly,
this unfoldase activity could be restored to WT-like levels using a low dose of p97
inhibitor CB-5083, providing initial evidence that p97 inhibitors might be effective
treatments for MSP (141).
To generalize our previous observations with A232E and further characterize
this accelerated unfoldase activity in MSP mutants, we expanded our analysis to six
additionalMSPmutations, all of which showedmoderately faster unfolding. We also
characterize the unfoldase activities of mixed WT and A232E hexamers for the first
time, disproving the hypothesis that mutant protomers can “poison” WT hexamers.
By examining ATPase rates during substrate processing in pure mutant and mixed
WT-mutant hexamers, we reveal that ATPase rates do not correlate with unfoldase
rates. Instead, we propose that the differential UN, and therefore substrate, binding
between WT and mutant hexamers described in Chapter 2 leads to the accelerated
unfoldase rates we observe. Taken together, our data lends further support for the
gain of function model for MSP pathology we previously proposed.
4.2 Results
Assay development
Our previous work employed a GFP-based substrate to demonstrate p97 un-
foldase activity; however, that this assay’s endpoint was dependent upon a mutant
GroEL “trap” to bind unfolded protein was a limitation (141). In order to improve
our assay, we redesigned our substrate, swapping in mEos3.2 for GFP (Figure 4.1A).
Upon exposure to UV light, mEos3.2 undergoes a backbone cleavage, forming two
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separate polypeptides and inducing a green-to-red fluorescence shift (161, 162). This
cleavage prevents protein refolding without the requirement for a GroEL “trap,” and
consequently others have employed mEos3.2 for studying p97 and its homologue
Cdc48 (163–165). As before, we modified a linear fusion of di-ubiquitin-mEos3.2
with long K48-linked ubiquitin chains for recognition by UN, allowing it to be
unfolded by p97-UN (141).
Figure 4.1: MSP unfoldase assay design. (A) Substrate design and unfoldase assay scheme. A linear fusion
of di-ubiquitin and mEos3.2 is irradiated with UV light, causing a backbone cleavage and fluorescence shift
in mEos3.2. Long, heterogeneous K48-linked ubiquitin chains are then built onto the substrate ubiquitins.
Unfolding of the substrate by p97-UN can be observed by the loss of fluorescence since the two polypeptides of
mEos3.2 cannot reassociate after processing. (B) MSP mutations used in this study. PDB #5FTK.
IBMPFD mutants have moderately enchanced unfoldase activities
In order to determine if faster unfolding of a model substrate is a definitive
characteristic of MSP mutations, we used our updated substrate to assess the un-
foldase activity of a total of seven MSP mutations, the locations of which on the
N-D1 interface are shown in Figure 4.1B. Under single turnover conditions, all
MSP mutants tested had accelerated unfoldase rates, ranging from approximately
115-160% of WT rates (Figure 4.2A-B, 4.3). This enhancement of activity was
seen across three independent preparations of proteins, though variability was high
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among different preparations of the mutant p97 proteins (Figure 4.4).
Figure 4.2: MSP mutants have moderately accelerated unfoldase rates. (A) Example unfoldase assay data
showing a loss of mEos3.2 fluorescence over time. Experiment was run under single-turnover conditions with
20 nM substrate, 400 nM p97 hexamer, and 800 nM UN. (B) Unfoldase data across a panel of seven MSP
mutations. Fluorescence data was fit to a single exponential, and rates were normalized to that of WT. Technical
replicates shown with a bar representing the average.
Figure 4.3: Single-turnover assays are at saturating concentrations of p97 and UN. (A) When the concentration
of p97 is halved, the rate of unfolding of WT is 98.5% ± 0.4% of original, while the rate of unfolding of A232E
is 93.7% ± 0.4% of original. (B) When the concentration of UN is doubled, the rate of unfolding of WT is
92.7% ± 0.3% of original, while the rate of unfolding of A232E is 93% ± 1% of original. Rates were determined
from single exponential fits. Error bars represent S.D. with n=3.
Figure 4.4: Prep-to-prep variability in MSP
mutant unfoldase rates. All MSP mutations
showed increased unfoldase rates compared
to WT, but large prep-to-prep variability ex-
ists within mutant proteins. For supplemen-
tary preps, all rates were normalized to that
of WT Supplementary Prep 1, and assays
were carried out in a modified assay buffer
under slightly different conditions than the
main text prep (see Methods). The main text
prep rates are repeated from Figure 4.2B.
Given the variability among protein preparations from our heterologous ex-
pression system, we wanted to investigate whether the observed enhancement in
MSP mutants can be recapitulated in proteins made in mammalian cells. To do so,
we expressed and purified p97-FLAG from Expi293 cells. Compared to a similar
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construct from E. coli, mammalian-made p97 was significantly faster at unfolding
our substrate and was able to unfold without the addition of purified UN (Figure
4.5A). Given that human p97 is decorated with PTMs (48, 166) and p97 from
mammalian cells can co-purify with adaptor proteins, these results are not surpris-
ing. Importantly, A232E made from a mammalian source is a faster unfoldase than
WT made from a mammalian source (Figure 4.5B), suggesting that our observa-
tions with bacterially-made proteins is not an artifact. Due to variability among
mammalian-expressed protein preparations that are technically difficult to control,
such as PTMs and co-purifying proteins, we chose to continue our characterization
of MSP mutations using proteins made in E. coli.
Figure 4.5: Mammalian-made A232E is a faster unfoldase thanWT. (A)Mammalian protein is a faster unfoldase
than bacterial protein and can promote unfolding without the addition of exogenous UN (red trace). Experiment
was carried out at 37 °C with 20 nM substrate, 250 nM p97 hexamer, and 500 nM UN. Error bars represent S.D.
with n = 2. (B) Mammalian-made A232E unfolds substrate faster than mammalian-made WT. Experiment was
carried out at 25 °C with 20 nM substrate, 2 µM p97 hexamer, and 2 µM UN. Error bars represent S.D. with
n=2.
MSP patients are heterozygous, so p97 hexamers comprising a mix of WT
and mutant protomers exist in cells. Therefore, we were interested in the ability of
mixed hexamers to unfold our model substrate. Three heterogeneous pools of mixed
hexamerswith increasing ratios ofA232E:WTprotomerswere purified as previously
described (Figure 2.7A). Mixed hexamers displayed unfoldase rates between those
of pure WT and A232E hexamers, and the unfoldase rate increased as the relative
number of mutant protomers increased (Figure 4.6).
ATPase activity does not correlate with unfoldase activity
Previous studies have shown MSP mutants have accelerated basal ATPase
activities (28, 117, 118); therefore, one potential explanation for accelerated unfold-
ing by MSP mutants is that they have simply higher enzymatic activity. To assess
this, we first examined the basal ATPase rates of the MSP mutants. As previously
reported in the literature, all MSP mutants have higher basal ATPase rates than
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Figure 4.6: Unfoldase rates correlate with the number of mutant subunits in a mixed hexamer. (A) Example
single-turnover unfoldase data with mixed hexamer fractions. An SDS-PAGE gel of Mixed 1-3 can be found in
Figure 2.7A. (B) Unfoldase data comparing mixed hexamers with pure WT and A232E hexamers. Fluorescence
data was fit to a single exponential, and rates were normalized to that of WT. Technical replicates shown with a
bar representing the average.
WT (Figure 4.7A). However, while processing substrate, the ATPase activity of p97
is stimulated (141, 163), so a comparison of these rates is more appropriate for
assessing a correlation between unfoldase rates and ATPase rates. Under saturating
concentrations of UN-substrate, mutants still have a higher ATPase rate than WT,
but the effect is much more subtle (up to 1.5-fold compared to 5- to 10-fold) (Figure
4.7B). These stimulated ATPase rates are not well correlated to unfoldase rate (Fig-
ure 4.7E), suggesting that mutants are not unfolding substrate faster because they
are consuming ATP faster.
Further underscoring this conclusion are similar analyses using mixed WT-
A232E hexamers. As expected, the basal ATPase rates of mixed hexamers increase
as the average number of mutant protomers in a hexamer increases (Figure 4.7B).
However, during substrate processing, all mixed hexamer populations have an es-
sentially identical ATPase rate in comparison to that of WT (Figure 4.7D). The
accelerated unfoldase rates of mixed WT-A232E hexamers do not correlate at all to
stimulated ATPase rates (Figure 4.7), implying again that ATP hydrolysis is not the
cause of accelerated unfolding by MSP mutants.
4.3 Discussion
Here we demonstrate that accelerated unfoldase activity is a defining feature
among p97 MSP mutations, supporting a gain of function model for p97-UN pro-
cesses. Our ATPase analysis of p97 during substrate processing provides strong
evidence that the accelerated basal ATPase rates of MSP mutants widely reported in
the literature is not a cause of disease but rather is an epiphenomenon. One caveat
to our stimulated ATPase assay is that our measurements were taken at time points
during which we expect, based on our single turnover rates, that p97 has completed
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Figure 4.7: MSP mutant ATPase rates do not correlate with unfoldase rates. (A, C) Basal ATPase rates
normalized to WT. (B, D) ATPase rates of 50 nM p97 stimulated by the presence of 250 nM UN-substrate,
normalized to that of WT (E) Plot of unfoldase rate versus stimulated ATPase rate. All values shown are
normalized to WT measurements. N ≥ 3 and error bars = s.d. WT and A232E data are repeated among panels.
one round of substrate unfolding. Because we do not include DUBs in our assays
(163), p97 is likely unable to efficiently turn over substrate, and consequently our
measurements may capture ATPase activity while p97 is stalled on ubiquitin chains
or otherwise dealing with product inhibition of new substrate unfolding. However,
we feel this rate still adequately reflects the ATPase rate while actively engaged by
a substrate. With stimulated ATPase rates being similar between WT and mutant
hexamers and identical between WT and WT-A232E mixed hexamers, we conclude
that ATP hydrolysis is not the rate-determining step of substrate unfolding in our
single turnover assays.
IfMSPmutants are not hydrolyzingATP faster, how then do they achieve faster
unfoldase rates? In Chapter 2, we discovered a 30- to 60-fold increased UN affinity
in mutant and a 10- to 30-fold increased UN affinity in WT-A232E mixed hexamers
compared to WT (Table 2.1, 2.2). Structural data suggests that this difference is
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caused by a shift in the up/down N domain equilibrium, with mutants favoring the
up conformation. Faster binding of UN, and hence faster binding of substrate, could
explain the accelerated single turnover rates we observe if the initiation of unfolding
is the rate-determining step. All three MSP mutants tested had similar UN affinities
in ATP (Table 2.2), yet they displayed unfoldase rates ranging from approximately
120-170% that of WT (Figure 4.2C). NMR studies of the up/down equilibrium
of p97 N domains revealed a continuum of perturbations among MSP mutations
(122), suggesting subtle differences in structure that could further affect substrate
engagement beyond UN binding. With such high UN affinity, mutants likely have
a disparate rate-determining step than WT that gives rise to rate differences. More
detailed mechanistic studies are needed to fully explore the kinetics of substrate
unfolding by p97 and how they are perturbed by MSP mutations.
MSP mutations are dominant, and this inheritance pattern could be explained
by a gain of function model or by a dominant negative model whereby mutant pro-
tomers poisonWThexamers. We demonstrated thatmixedWT-mutant hexamers are
fully functional and, like pure mutant hexamers, display faster unfolding than WT,
lending evidence to support a gain of function model for UN-dependent processes.
These biochemical results support a few potential models for MSP pathology. First,
an increase in UN binding from perturbed up/down N-domain equilibrium could
cause disease by enhancing p97-UN-dependent processes, leading to the inappro-
priate degradation of protein targets. Some support for this model exists in the MSP
literature. Studies on a mouse model of MSP demonstrated increased turnover of
IκB-α, leading to the improper activation of NF-κB signaling (110). Degradation
of IκB-α is dependent upon the p97-UN complex, suggesting that overactivation
of p97-UN could explain this phenotype (84, 167, 168). Similarly, increased pro-
cessing of TDP-43 and mitofusion in MSP mutants have been demonstrated in
Drosophila (108, 169). Another consequence of p97-UN overactivation could be
the formation of detrimental aggregates if the proteasome is unable to handle an in-
crease in unfolded protein products. Aggregates decorated with ubiquitin are found
in tissues affected by MSP (84), suggesting an overburdened proteasome.
However, the p97 system is extremely complex, and we cannot discount
other hypothesis for MSP pathology that are consistent with our biochemistry.
An alternative hypothesis for disease is that the adaptor imbalance itself causes
problems for the cell. Based on published estimations (87, 170, 171) and our
affinity measurements, in WT cells we expect intracellular concentrations to be
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approximately 60 nM free UN, 420 nM free p97, and 80 nM p97-UN complex.
However, in the mutant cells we would expect essentially all of the UN to be in
complex with p97, forming intracellular concentrations of 360 nM free p97 and
140 nM p97-UN complex. If free UN is necessary for initial substrate binding,
as has been suggested for mitophagy (97), the lack of this pool in mutant cells
could cause a loss of p97-UN dependent functions. Alternatively, with less free p97
available to bind other adaptors, this imbalance of UN binding could cause a loss
of function in other p97-dependent pathways (116, 125). Additionally, we cannot
rule out that our gain of p97-UN function is an epiphenomenon whereas gain or
loss of function with another p97 adaptor is responible for pathology. In particular,
UBXD1 has decreased binding to MSP mutants due to their preference for the N
domain down conformation (58, 121, 122), and failures in lysosomal degradation
have been associated with MSP mutations (58, 103, 107, 172).
If indeed MSP is caused by a gain of function in p97-UN-dependent path-
ways, a p97 inhibitor could be an effective treatment for MSP. Though an inhibitor
would not rectify the causal defect—abberant N domain conformations and adap-
tor binding—it would minimize the harmful downstream effects of increased UN
binding. We demonstrated this proof of concept by showing that a low concen-
tration of the p97 inhibitor CB-5083 was able to restore WT-like unfolding in the
MSP mutant A232E in vitro (141). Such an approach was also demonstrated to
be viable in Drosophila, where physiological and morphological defects in mus-
cle tissue caused by the expression of mutant p97 were reversed through treatment
with low doses of p97 inhibitor (108). Currently, there is no treatment for MSP,
but our biochemical work suggests an exciting potential therapeutic avenue. More
cell-based experiments are needed to distinguish among these hypotheses to identify
the molecular basis for MSP pathology and explore whether p97 inhibitors may be
effective treatments.
4.4 Methods
Protein expression and purification
Expression, purification, and labeling of UN and p97-His were carried out
as previously described (141). MSP mutations of these constructs were carried out
using site-directed mutagenesis and prepared like WT.
A plasmid encoding p97-A232E-FLAGwas made through site directed muta-
genesis of a plasmid encodingWTp97-FLAGunder theCMVpromoter (RDB#2946).
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Expi293 suspension cells were grown in Expi293 Expression Medium (Thermo
Fisher) at 37°C with 8% CO2. Cells were transfected with 1.1 mg DNA per 1 L
of cells using polyethyleneimine “Max” (MW 40,000) (Polysciences) at a ratio of
1:2.7 DNA:PEI. After 72 hours, cells were harvested at 3000g for 15 minutes and
washed once with 30 mL cold PBS. Cell pellet was resuspended in lysis buffer (50
mM Tris pH 7.4, 150 mM KCl, 5 mM MgCl2, 5% glycerol, 0.5% Triton X-100)
with protease inhibitors (Roche) and incubated with rotation at 4 °C for 30 minutes.
Clarified lysate was incubated with 2 mL of anti-FLAG resin (Sigma) at 4 °C for 1.5
hours. Resin was washed with three column volumes of wash buffer (50 mM Tris
pH 7.4, 400 mMKCl, 5 mMMgCl2, 0.5% Triton X-100) three times for ten minutes
with rotation followed by one wash with elution buffer without FLAG peptide (25
mM Hepes pH 7.4, 150 mM KCl, 2 mM MgCl2). Protein was eluted with 2 mL
of elution buffer containing 0.2 mg/mL 3XFLAG peptide for ten minutes with rota-
tion. Elution was repeated, and resin was drained with a final 2 mL of elution buffer.
Protein was concentrated and exchanged into storage buffer (20 mM Hepes pH 7.4,
250 mM KCl, 1 mM MgCl2, 5% glycerol, 0.5 mM TCEP) before flash freezing.
Substrate preparation
His6-UbG76V-UbG76V-mEos3.2 was constructed by replacing GFP in the pre-
viously published His6-UbG76V-UbG76V-GFP substrate (RDB 3344) (141) with a
PCR amplicon of mEos3.2 using BamHI and NotI restriction sites. Protein was
expressed in BL21(DE3) overnight at 18 °C. Cells were lysed by sonication in 50
mM Tris pH 8.0, 250 mM NaCl, 20 mM imidazole, 2 mM 2-mercaptoethanol, and
protease inhibitors (Roche), and clarified lysate was incubated with Ni-NTA resin
for 2 hours at 4 °C. After elution from the resin with 200 mM imidazole, protein
was spin concentrated and dialyzed overnight into 50 mM Hepes pH 7.0, 150 mM
NaCl, 2 mM 2-mercaptoethanol. Sample was irradiated with 380 nm LED light
(Thorlabs) for one hour at 4 °C. After filtration, protein was purified on a Superdex
200 column (20 mM Hepes pH 7.4, 100 mM KCl, 3 mM MgCl2), and fractions
were pooled, concentrated and flash frozen. Ubiquitylation and purification of the
ubiquitylated substrate was carried out as previously described (141). Final sub-
strate showed approximately 40% photocleavage as measured by absorbance at 507
and 572 nm (162). Concentrations of substrate referred to in this paper correspond
to the concentration of photocleaved (red) protein.
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Unfoldase assays
Experiments were carried out in Assay Buffer (20 mM Hepes pH 7.4, 150
mM KCl, 20 mM MgCl2, 1 mM TCEP, 1 mg/mL BSA) supplemented with ATP
regeneration system (5 mM ATP, 30 mM creatine phosphate, 50 µg/mL creatine
phosphokinase). Proteins were preincubated in a 96-well plate (Costar 3694) for
15 minutes at 37 °C before the addition of ATP regeneration system to initiate the
reaction. Final concentrations were 20 nM substrate, 400 nM p97 hexamer, and 800
nM UN. Fluorescence was read on a PHERAstar Plus (BMG Labtech) or Synergy
Neo2 (BioTek) plate reader using a 540 nm excitation filter and 590 nm emission
filter. Data were normalized to the first reading and fit to a single exponential decay
equation to extract an unfolding rate.
ATPase assays
Proteins (100-400 nM p97) were diluted in assay buffer and preincubated in
a 96-well plate (Costar 3695) for 10 minutes at 37 °C before the addition of ATPase
mix (5mMATP, 1mMNADH, 7.5mMPEP, 50Xdilution PK/LDH (SigmaP0294)).
For stimulated ATPase rates, final concentrations were 50 nM p97, 250 nMUN, and
250 nM substrate. After 15 minutes, A340 was monitored for ten minutes, converted
to an NADH concentration, and fit to a line to determine the ATPase rate. A WT
p97 control was included in every plate and used to normalize ATPase rates.
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